@NP	bone marrow derived mesenchymal stem cells -LRB- NIMSCs -RRB-	612
@NP	bone marrow derived mesenchymal stem cells	612
@NP	bone marrow	612
@NP	mesenchymal stem cells	632
@NP	NIMSCs	656
@NP	olfactory ensheathing cells	675
@NP	OECs	704
@NP	a rat model of sub-acute spinal cord injury	731
@NP	a rat model	731
@NP	sub-acute spinal cord injury	746
@NP	the behavioral and histological analyses	779
@NP	A balloon-compression technique	836
@NP	an injury at T8 -- T9 level of spinal cord	888
@NP	an injury at T8	888
@NP	an injury	888
@NP	T8	901
@NP	T9 level of spinal cord	904
@NP	T9 level	904
@NP	spinal cord	916
@NP	a week post injury	935
@NP	rats	955
@NP	either NIMSCs or OECs	979
@NP	the center	1004
@NP	lesion cavity , 3 mm cranial and 3 mm caudal	1029
@NP	lesion cavity	1029
@NP	3 mm cranial	1044
@NP	3 mm caudal	1061
@NP	the cavity	1076
@NP	Weekly behavioral assessment using BBB score	1088
@NP	Weekly behavioral assessment	1088
@NP	BBB score	1123
@NP	five-week period post transplantation	1147
@NP	histological assessment	1197
@NP	labeled cells	1245
@NP	the tissue	1262
@NP	the reduction of cavity formation and axonal regeneration	1294
@NP	the reduction	1294
@NP	cavity formation and axonal regeneration	1311
@NP	cavity formation	1311
@NP	axonal regeneration	1332
@NP	Evaluation of locomotor performance	1353
@NP	Evaluation	1353
@NP	locomotor performance	1367
@NP	significant behavioral improvement	1396
@NP	NIMSC group	1434
@NP	OEC and control groups	1451
@NP	The histological analyses	1475
@NP	the presence of transplanted cells in the spinal cord parenchyma	1510
@NP	the presence	1510
@NP	transplanted cells in the spinal cord parenchyma	1526
@NP	transplanted cells	1526
@NP	the spinal cord parenchyma	1548
@NP	Volume of injured area that was occupied with syrinx cavity in NIMSC group	1576
@NP	Volume	1576
@NP	injured area that was occupied with syrinx cavity in NIMSC group	1586
@NP	injured area	1586
@NP	syrinx cavity in NIMSC group	1622
@NP	syrinx cavity	1622
@NP	NIMSC group	1639
@NP	control group	1679
@NP	addition	1697
@NP	neurofilament-positive axons	1717
@NP	higher expression	1767
@NP	rats receiving NIMSC compared to the other two groups	1788
@NP	rats	1788
@NP	NIMSC compared to the other two groups	1803
@NP	NIMSC	1803
@NP	the other two groups	1821
@NP	conclusion NIMSC	1846
@NP	both behavioral and histological improvement that potentially makes them	1870
@NP	them	1938
@NP	a promising candidate for cell therapy approaches of spinal cord injuries	1943
@NP	a promising candidate	1943
@NP	cell therapy approaches of spinal cord injuries	1969
@NP	cell therapy approaches	1969
@NP	spinal cord injuries	1996
@NP	Introduction Spinal cord injury -LRB- SCI -RRB-	2022
@NP	Introduction Spinal cord injury	2022
@NP	Introduction	2022
@NP	Spinal cord injury	2035
@NP	SCI	2055
@NP	a debilitating disorder	2063
@NP	high social , psychological and financial burden	2096
@NP	patients , families and governments	2147
@NP	This disorder	2183
@NP	paraplegia or quadriplegia	2211
@NP	the trauma site	2251
@NP	sensation	2279
@NP	Most of these patients	2290
@NP	Most	2290
@NP	these patients	2298
@NP	difficulty in controlling urination and defecation	2318
@NP	difficulty	2318
@NP	urination and defecation	2344
@NP	The importance of regenerative medicine	2370
@NP	The importance	2370
@NP	regenerative medicine	2388
@NP	peripheral nervous system -LRB- PNS -RRB-	2461
@NP	peripheral nervous system	2461
@NP	PNS	2488
@NP	the central nervous system -LRB- CNS -RRB-	2494
@NP	the central nervous system	2494
@NP	CNS	2522
@NP	no capacity	2531
@NP	regeneration	2547
@NP	turn	2570
@NP	inhibitory factors	2589
@NP	the damaged area -LRB- Filbin , 2003 -RRB-	2633
@NP	the damaged area	2633
@NP	Filbin , 2003	2651
@NP	Filbin	2651
@NP	2003	2659
@NP	addition	2669
@NP	secondary neurodegeneration	2679
@NP	place	2713
@NP	the surrounding tissue site due to inflammatory factors	2722
@NP	the surrounding tissue site	2722
@NP	inflammatory factors	2757
@NP	substantially the prognosis -LRB- Andrade et al. , 2008 -RRB-	2791
@NP	substantially the prognosis	2791
@NP	Andrade	2820
@NP	et al. , 2008	2828
@NP	et al.	2828
@NP	2008	2836
@NP	High dose corticosteroid injection within 48 h after damage	2843
@NP	High dose corticosteroid injection	2843
@NP	48 h after damage	2885
@NP	48 h	2885
@NP	damage	2896
@NP	the only accepted clinical method	2906
@NP	consequences of spinal damages -LRB- Bracken , 2001 -RRB-	2950
@NP	consequences	2950
@NP	spinal damages -LRB- Bracken , 2001 -RRB-	2966
@NP	spinal damages	2966
@NP	Bracken	2982
@NP	2001	2991
@NP	Cell therapy	2998
@NP	an issue that has raised much hope in regeneration of CNS and PNS	3014
@NP	an issue	3014
@NP	much hope	3039
@NP	regeneration of CNS and PNS	3052
@NP	regeneration	3052
@NP	CNS and PNS	3068
@NP	various cell types	3090
@NP	CNS	3138
@NP	Stem cells	3143
@NP	the capacity of self renewal and differentiation to different cell types	3159
@NP	the capacity	3159
@NP	self renewal and differentiation	3175
@NP	different cell types	3211
@NP	key cells	3250
@NP	neural regeneration	3264
@NP	Kim and de Vellis , 2009 ; Rossi and Keirstead , 2009	3285
@NP	Kim and de Vellis	3285
@NP	Kim	3285
@NP	de Vellis	3293
@NP	Vellis	3296
@NP	2009 ; Rossi	3304
@NP	2009	3304
@NP	Rossi	3310
@NP	Keirstead , 2009	3320
@NP	Keirstead	3320
@NP	2009	3331
@NP	Neural stem cells -LRB- Einstein and Ben-Hur , 2008 -RRB-	3338
@NP	Neural stem cells	3338
@NP	Einstein and Ben-Hur	3357
@NP	2008	3379
@NP	embryonic stem cells -LRB- McDonald et al. , 2004 -RRB-	3386
@NP	embryonic stem cells	3386
@NP	McDonald	3408
@NP	et al. , 2004	3417
@NP	et al.	3417
@NP	2004	3425
@NP	mesenchymal stem cells -LRB- MSCs -RRB- -LRB- Vaquero and Zurita , 2009 -RRB-	3432
@NP	mesenchymal stem cells -LRB- MSCs -RRB-	3432
@NP	mesenchymal stem cells	3432
@NP	MSCs	3456
@NP	Vaquero and Zurita	3463
@NP	2009	3483
@NP	pluripotent hair follicle stem cells	3493
@NP	Liu	3531
@NP	et al. , 2011	3535
@NP	et al.	3535
@NP	2011	3543
@NP	CNS	3573
@NP	different levels of success	3582
@NP	different levels	3582
@NP	success	3602
@NP	recent years	3614
@NP	MSCs	3628
@NP	the spotlight of cell therapy	3646
@NP	the spotlight	3646
@NP	cell therapy	3663
@NP	various remarkable properties	3687
@NP	they	3717
@NP	lack of immunologic rejection	3736
@NP	lack	3736
@NP	immunologic rejection	3744
@NP	strong secretory properties and their plasticity	3774
@NP	strong secretory properties	3774
@NP	their plasticity	3806
@NP	different cell types -LRB- Caplan , 2007 -RRB-	3839
@NP	different cell types	3839
@NP	Caplan	3861
@NP	2007	3869
@NP	stem cells	3884
@NP	more recently lineage committed stem cells	3896
@NP	lineage	3910
@NP	CNS regeneration	3963
@NP	Lu et al. , 2006 ; Marques et al. , 2010 ; Ye et al. , 2007	3981
@NP	Lu	3981
@NP	et al. , 2006 ; Marques et al. , 2010 ; Ye et al. , 2007	3984
@NP	et al. , 2006	3984
@NP	et al.	3984
@NP	2006	3992
@NP	Marques et al. , 2010	3998
@NP	Marques	3998
@NP	et al. , 2010	4006
@NP	et al.	4006
@NP	2010	4014
@NP	Ye et al. , 2007	4020
@NP	Ye	4020
@NP	et al. , 2007	4023
@NP	et al.	4023
@NP	2007	4031
@NP	our previous study	4041
@NP	we	4061
@NP	transplantation of neurally induced MSC into the sub-acute model of SCI	4076
@NP	transplantation	4076
@NP	MSC	4112
@NP	the sub-acute model of SCI	4121
@NP	the sub-acute model	4121
@NP	SCI	4144
@NP	significant behavioral improvement	4155
@NP	undifferentiated MSC -LRB- Pedram et al. , 2009 -RRB-	4207
@NP	undifferentiated MSC	4207
@NP	Pedram	4229
@NP	et al. , 2009	4236
@NP	et al.	4236
@NP	2009	4244
@NP	Glial cells such as schwann cells and olfactory ensheathing cells	4251
@NP	Glial cells	4251
@NP	schwann cells and olfactory ensheathing cells	4271
@NP	schwann cells	4271
@NP	olfactory ensheathing cells	4289
@NP	OECs	4318
@NP	spinal cord regeneration	4351
@NP	some other studies	4381
@NP	their positive effect	4408
@NP	CNS regeneration	4433
@NP	García-Alías et al. , 2004 ; Kocsis et al. , 2009 ; Ramer et al. , 2004	4451
@NP	García-Alías	4451
@NP	et al. , 2004 ; Kocsis et al. , 2009 ; Ramer et al. , 2004	4464
@NP	et al. , 2004	4464
@NP	et al.	4464
@NP	2004	4472
@NP	Kocsis et al. , 2009	4478
@NP	Kocsis	4478
@NP	et al. , 2009	4485
@NP	et al.	4485
@NP	2009	4493
@NP	Ramer et al. , 2004	4499
@NP	Ramer	4499
@NP	et al. , 2004	4505
@NP	et al.	4505
@NP	2004	4513
@NP	OECs	4520
@NP	unique glial cells	4529
@NP	the olfactory systems	4557
@NP	olfactory neurogenesis and the retargeting	4592
@NP	olfactory neurogenesis	4592
@NP	the retargeting	4619
@NP	the PNS/CNS boundary in the olfactory system	4642
@NP	the PNS/CNS boundary	4642
@NP	the olfactory system	4666
@NP	These cells	4688
@NP	tissue sparing and neuroprotection	4722
@NP	outgrowth of both intact and lesioned axons	4766
@NP	outgrowth	4766
@NP	both intact and lesioned axons	4779
@NP	angiogenesis and remyelinate axons	4820
@NP	a range of demyelinating insults -LRB- Richter and Roskams , 2008 -RRB-	4861
@NP	a range	4861
@NP	demyelinating insults -LRB- Richter and Roskams , 2008 -RRB-	4872
@NP	demyelinating insults	4872
@NP	Richter and Roskams	4895
@NP	2008	4916
@NP	this study	4926
@NP	we	4938
@NP	transplantation of NIMSC and OECs	4950
@NP	transplantation	4950
@NP	NIMSC and OECs	4969
@NP	a sub-acute model of SCI	4987
@NP	a sub-acute model	4987
@NP	SCI	5008
@NP	rats	5015
@NP	the regeneration of neural tissue	5041
@NP	the regeneration	5041
@NP	neural tissue	5061
@NP	the damaged area	5078
@NP	Material and methods 2.1 .	5100
@NP	Material and methods	5100
@NP	2.1	5121
@NP	Isolation and culture of primary rat OECs Highly purified cultures of OEC	5126
@NP	Isolation and culture	5126
@NP	primary rat OECs Highly purified cultures of OEC	5151
@NP	primary rat OECs	5151
@NP	cultures of OEC	5184
@NP	cultures	5184
@NP	OEC	5196
@NP	the nerve fiber layer of the olfactory bulb of neonatal rats	5219
@NP	the nerve fiber layer	5219
@NP	the olfactory bulb of neonatal rats	5244
@NP	the olfactory bulb	5244
@NP	neonatal rats	5266
@NP	a procedure	5286
@NP	Ramon-Cueto	5317
@NP	et al. -LRB- 1998 -RRB-	5329
@NP	et al.	5329
@NP	1998	5337
@NP	Pearse	5365
@NP	et al. -LRB- 2007 -RRB-	5372
@NP	et al.	5372
@NP	2007	5380
@NP	the pia	5396
@NP	so much care	5421
@NP	the inclusion of any bulb nerve fiber	5446
@NP	the inclusion	5446
@NP	any bulb nerve fiber	5463
@NP	Tissue	5485
@NP	trypsin and collagenase -LRB- both from Gibcoo , USA -RRB-	5525
@NP	trypsin and collagenase	5525
@NP	both from Gibcoo , USA	5550
@NP	both	5550
@NP	Gibcoo , USA	5560
@NP	the	5577
@NP	cells	5593
@NP	forskolin	5615
@NP	0.8 g/mL	5626
@NP	Sigma	5637
@NP	USA	5644
@NP	pituitary extract	5653
@NP	2 mg/mL	5672
@NP	DMEM/F12/10 % FBS -LRB- Sigma , USA -RRB- for 5 days	5684
@NP	DMEM/F12/10 % FBS -LRB- Sigma , USA -RRB-	5684
@NP	DMEM/F12/10 % FBS	5684
@NP	Sigma	5702
@NP	USA	5709
@NP	5 days	5718
@NP	final purification	5733
@NP	p75 immunopanning as previously described -LRB- Takami et al. , 2002 -RRB-	5755
@NP	p75 immunopanning	5755
@NP	Takami	5798
@NP	et al. , 2002	5805
@NP	et al.	5805
@NP	2002	5813
@NP	Cells	5820
@NP	confluence	5840
@NP	passage 3	5864
@NP	The purity of the cells	5875
@NP	The purity	5875
@NP	the cells	5889
@NP	p75 antibody -LRB- Rabbit polyclonal , Abcam , USA -RRB-	5919
@NP	p75 antibody	5919
@NP	Rabbit polyclonal , Abcam , USA	5933
@NP	Rabbit polyclonal	5933
@NP	Abcam , USA	5952
@NP	the OECs	5989
@NP	transplantation	6004
@NP	cells	6021
@NP	72 h with bromodeoxyuridine	6047
@NP	72 h	6047
@NP	bromodeoxyuridine	6057
@NP	BrdU	6076
@NP	10 g/mL	6082
@NP	Sigma , USA	6092
@NP	engraftment	6112
@NP	Gratzner , 1982	6125
@NP	Gratzner	6125
@NP	1982	6135
@NP	Unincorporated BrdU	6142
@NP	a thymidine analog and marker of newly synthesized DNA	6172
@NP	a thymidine analog and marker	6172
@NP	newly synthesized DNA	6205
@NP	extensive washing before transplantation	6244
@NP	extensive	6244
@NP	transplantation	6269
@NP	2.2	6286
@NP	Isolation and culture of primary rat MSCs MSCs	6291
@NP	Isolation and culture	6291
@NP	primary rat MSCs MSCs	6316
@NP	adult female wistar rat -LRB- weight = 90 -- 100 g -RRB-	6357
@NP	adult female wistar rat	6357
@NP	weight	6382
@NP	= 90 -- 100 g	6389
@NP	= 90	6389
@NP	100 g	6394
@NP	a modified procedure described previously -LRB- Hofstetter et al. , 2002 -RRB-	6407
@NP	a modified procedure described previously	6407
@NP	a modified procedure	6407
@NP	Hofstetter	6450
@NP	et al. , 2002	6461
@NP	et al.	6461
@NP	2002	6469
@NP	brief	6479
@NP	anesthetization and euthanization of rats	6492
@NP	anesthetization and euthanization	6492
@NP	rats	6529
@NP	femures and tibias	6535
@NP	distal epiphyses	6585
@NP	An 18-guage needle	6616
@NP	the proximal end of the bone	6653
@NP	the proximal end	6653
@NP	the bone	6673
@NP	marrow	6686
@NP	sterile cryovials	6710
@NP	ice	6742
@NP	The whole bone marrow suspension	6747
@NP	T25 flasks	6796
@NP	The cells	6808
@NP	DMEM/F12	6840
@NP	10 % FBS and 1 % penicillin/streptomycin	6860
@NP	10 % FBS	6860
@NP	1 % penicillin/streptomycin	6872
@NP	3 days	6906
@NP	cells	6930
@NP	the fresh medium in new flasks	6972
@NP	the fresh medium	6972
@NP	new flasks	6992
@NP	Cells	7004
@NP	confluence	7024
@NP	passage 3	7047
@NP	cell surface antigen characterization	7062
@NP	MSC antigens	7101
@NP	flowcytometry using fluorescein	7131
@NP	flowcytometry	7131
@NP	fluorescein	7151
@NP	isothio-cyanate-conjugated -LRB- FITC -RRB- mouse	7163
@NP	FITC	7191
@NP	anti-rat CD31 -LRB- AbD Serotec , UK -RRB-	7203
@NP	anti-rat CD31	7203
@NP	AbD Serotec	7218
@NP	UK	7231
@NP	CD44 -LRB- Cedarlane , Canada -RRB-	7239
@NP	CD44	7239
@NP	Cedarlane	7245
@NP	Canada	7256
@NP	phycoerythrin-conjugated -LRB- PE -RRB- mouse anti-rat CD45	7265
@NP	phycoerythrin-conjugated -LRB- PE -RRB- mouse	7265
@NP	PE	7291
@NP	anti-rat CD45	7301
@NP	BioLegend	7316
@NP	USA	7327
@NP	CD90 -LRB- eBioscience , USA -RRB-	7333
@NP	CD90	7333
@NP	eBioscience	7339
@NP	USA	7352
@NP	CD73 -LRB- BD Biosciences , USA -RRB-	7361
@NP	CD73	7361
@NP	BD Biosciences	7367
@NP	USA	7383
@NP	Multilineage differentiation potential	7389
@NP	the ability	7452
@NP	bone marrow	7467
@NP	MSCs	7487
@NP	adipocytes and osteoblasts	7514
@NP	Pittenger	7567
@NP	et al. , 1999	7577
@NP	et al.	7577
@NP	1999	7585
@NP	Oil red O and alizarin red staining	7592
@NP	Oil red O	7592
@NP	alizarin red staining	7606
@NP	adipocytes and osteoblasts	7653
@NP	A recombinant adenovirus	7695
@NP	the green fluorescent protein -LRB- GFP -RRB- gene	7729
@NP	GFP	7760
@NP	MSCs transduction as described previously -LRB- Satake et al. , 2004 -RRB-	7783
@NP	MSCs transduction	7783
@NP	Satake	7826
@NP	et al. , 2004	7833
@NP	et al.	7833
@NP	2004	7841
@NP	that	7854
@NP	the time of transduction	7863
@NP	the time	7863
@NP	transduction	7875
@NP	day 1 , 2 mL of virus solution and 2 mL of complete medium	7900
@NP	day 1	7900
@NP	2 mL of virus solution	7907
@NP	2 mL	7907
@NP	virus solution	7915
@NP	2 mL of complete medium	7934
@NP	2 mL	7934
@NP	complete medium	7942
@NP	final 108 plaque	7959
@NP	unit -LRB- PFU -RRB-	7984
@NP	unit	7984
@NP	PFU	7990
@NP	106 cells	8016
@NP	24 h incubation at 37 ◦ C	8033
@NP	24 h incubation	8033
@NP	37 ◦ C	8052
@NP	virus solution	8059
@NP	complete fresh medium	8090
@NP	2 -- 3 days post transduction	8119
@NP	2	8119
@NP	3 days post transduction	8121
@NP	3 days	8121
@NP	post transduction	8128
@NP	MSCs	8147
@NP	0.3 % collagenase/DMEM	8172
@NP	1 min followed by 0.05 % trypsin/0 .03 % EDTA for 5 min	8198
@NP	1 min	8198
@NP	0.05 % trypsin/0 .03 % EDTA for 5 min	8216
@NP	0.05 % trypsin/0 .03 % EDTA	8216
@NP	0.05 % trypsin/0 .03 %	8216
@NP	0.05 %	8216
@NP	trypsin/0 .03 %	8222
@NP	5 min	8245
@NP	Fluorescent microscopy	8252
@NP	cells	8299
@NP	transplantation	8336
@NP	2.3	8353
@NP	Neural differentiation of MSCs MSCs	8358
@NP	Neural differentiation	8358
@NP	MSCs MSCs	8384
@NP	neurons	8410
@NP	a modified procedure	8424
@NP	details -LRB- Deng et al. , 2001 -RRB-	8469
@NP	details	8469
@NP	Deng	8478
@NP	et al. , 2001	8483
@NP	et al.	8483
@NP	2001	8491
@NP	brief	8501
@NP	the cells	8508
@NP	DMEM/F12	8535
@NP	0.5 mM 3-isobutyl - 1-methylxanthine -LRB- IBMX , Sigma , USA -RRB-	8555
@NP	0.5 mM 3-isobutyl	8555
@NP	1-methylxanthine -LRB- IBMX , Sigma , USA -RRB-	8574
@NP	1-methylxanthine	8574
@NP	IBMX	8592
@NP	Sigma	8598
@NP	USA	8605
@NP	1 mM retinoid acid -LRB- RA , Sigma , USA -RRB- for 7 days	8614
@NP	1 mM retinoid acid -LRB- RA , Sigma , USA -RRB-	8614
@NP	1 mM retinoid acid	8614
@NP	RA	8634
@NP	Sigma	8638
@NP	USA	8645
@NP	7 days	8654
@NP	All culture media	8662
@NP	every 2 -- 3 days	8693
@NP	every 2	8693
@NP	3 days	8701
@NP	7 days of induction	8715
@NP	7 days	8715
@NP	induction	8725
@NP	cells	8736
@NP	engraftment	8757
@NP	transplantation	8777
@NP	the cells	8794
@NP	any changes in morphology and production of neural specific proteins	8822
@NP	any changes	8822
@NP	morphology and production of neural specific proteins	8837
@NP	morphology and production	8837
@NP	neural specific proteins	8866
@NP	the induced cells	8902
@NP	4 % paraformaldehyde	8936
@NP	20 min , permeabilized with Triton X-100 -LRB- 0.2 % -RRB-	8960
@NP	20 min	8960
@NP	permeabilized with Triton X-100 -LRB- 0.2 % -RRB-	8968
@NP	permeabilized with Triton X-100	8968
@NP	Triton	8987
@NP	0.2 %	9001
@NP	immunocytochemistry	9020
@NP	mouse monoclonal anti-beta-tubulin III -LRB- 1:50 , Abcam , USA -RRB-	9046
@NP	mouse monoclonal	9046
@NP	III	9081
@NP	1:50	9086
@NP	Abcam	9092
@NP	USA	9099
@NP	mouse monoclonal anti-myelin	9105
@NP	protein 2 -LRB- MAP2 , 1:50 , Abcam , USA -RRB-	9145
@NP	protein 2	9145
@NP	MAP2	9156
@NP	1:50	9162
@NP	Abcam , USA	9168
@NP	FITC-conjugated anti-mouse secondary antibody -LRB- 1:500 , Sigma , USA -RRB-	9184
@NP	FITC-conjugated anti-mouse secondary antibody	9184
@NP	1:500	9231
@NP	Sigma	9238
@NP	USA	9245
@NP	2.4	9251
@NP	Induction	9256
@NP	spinal cord injury Adult female wistar rats	9269
@NP	n	9314
@NP	= 21 , weight 300 -- 350 g	9316
@NP	= 21	9316
@NP	weight 300	9322
@NP	350 g	9333
@NP	spinal contusion injury	9349
@NP	Fogarty catheter	9379
@NP	previously -LRB- Vanicky ' et al. , 2001	9408
@NP	previously -LRB- Vanicky ' et al.	9408
@NP	previously	9408
@NP	Vanicky ' et al.	9420
@NP	Vanicky '	9420
@NP	et al.	9429
@NP	2001	9437
@NP	laminotomy	9453
@NP	T10 vertebral level in anesthetized rats	9476
@NP	T10 vertebral level	9476
@NP	anesthetized rats	9499
@NP	dental drill	9523
@NP	A two French Fogarty catheter	9537
@NP	two	9539
@NP	saline	9583
@NP	an air	9607
@NP	tight 50 µl hamilton syringe	9614
@NP	tight 50 µl	9614
@NP	50	9620
@NP	hamilton syringe	9626
@NP	a precise sampling device	9652
@NP	The catheter	9679
@NP	the epidural space	9710
@NP	1 cm	9756
@NP	the center of the balloon	9770
@NP	the center	9770
@NP	the balloon	9784
@NP	T8	9806
@NP	T9 level of the spinal cord	9809
@NP	T9 level	9809
@NP	the spinal cord	9821
@NP	The balloon	9838
@NP	a defined volume of saline -LRB- 15 µl -RRB- for 5 min	9881
@NP	a defined volume	9881
@NP	saline -LRB- 15 µl -RRB- for 5 min	9901
@NP	saline -LRB- 15 µl -RRB-	9901
@NP	saline	9901
@NP	15 µl	9909
@NP	5 min	9920
@NP	that	9933
@NP	catheter	9939
@NP	muscles and skin	9979
@NP	layers	10011
@NP	surgery	10025
@NP	rats	10034
@NP	large cages	10058
@NP	Manual bladder expression	10071
@NP	reflex bladder	10138
@NP	Antibiotic therapy with enrofloxacin -LRB- 10 mg/kg , every 24 h -RRB-	10170
@NP	Antibiotic therapy with enrofloxacin	10170
@NP	Antibiotic therapy	10170
@NP	enrofloxacin	10194
@NP	10 mg/kg , every 24 h	10208
@NP	10 mg/kg	10208
@NP	every 24 h	10218
@NP	one	10250
@NP	week	10254
@NP	All experiments	10260
@NP	the guidelines of the Iran Animal Care Committee	10285
@NP	the guidelines	10285
@NP	the Iran Animal Care Committee	10303
@NP	the faculty of veterinary medicine animal care committee	10355
@NP	the faculty	10355
@NP	veterinary medicine animal care committee	10370
@NP	2.5	10413
@NP	implantation , GFP-transduced NIMSCs and BrdU	10443
@NP	implantation	10443
@NP	GFP-transduced NIMSCs	10457
@NP	BrdU	10483
@NP	culture via trypsinization	10522
@NP	culture	10522
@NP	trypsinization	10534
@NP	cells	10555
@NP	fresh DMEM/F12	10594
@NP	Appropriate aliquots of cells	10622
@NP	Appropriate aliquots	10622
@NP	cells	10646
@NP	ice	10665
@NP	surgery	10678
@NP	One week	10687
@NP	SCI	10702
@NP	the rats	10707
@NP	a small hole	10738
@NP	the vertebral arches of T8 and/or T9	10763
@NP	the vertebral arches	10763
@NP	T8 and/or T9	10787
@NP	T8	10787
@NP	T9	10797
@NP	a micromotor	10806
@NP	The tip of a 20 µl hamilton syringe connected to a microinjector	10820
@NP	The tip	10820
@NP	a 20 µl hamilton syringe	10831
@NP	a microinjector	10869
@NP	the intact dura	10906
@NP	the center	10927
@NP	the developing lesion cavity	10941
@NP	3 mm cranial	10971
@NP	3 mm caudal	10988
@NP	the cavity	11003
@NP	penetration depth of 1.0 mm at an angle of 40 -- 45 ◦ past	11015
@NP	penetration depth	11015
@NP	1.0 mm at an angle of 40 -- 45 ◦ past	11036
@NP	1.0 mm	11036
@NP	an angle of 40 -- 45 ◦ past	11046
@NP	an angle of 40	11046
@NP	an angle	11046
@NP	40	11058
@NP	45 ◦ past	11061
@NP	45 ◦	11061
@NP	past	11065
@NP	The rate of injection	11086
@NP	The rate	11086
@NP	injection	11098
@NP	2 µl/min	11112
@NP	The hamilton syringe	11122
@NP	place for an additional 1 min	11155
@NP	place	11155
@NP	an additional 1 min	11165
@NP	leakage	11197
@NP	withdrawal	11210
@NP	Rats	11222
@NP	3 groups	11254
@NP	group I , 1 × 106 NIMSCs -LRB- n = 7 -RRB- and in group II	11267
@NP	group I	11267
@NP	1 × 106 NIMSCs -LRB- n = 7 -RRB-	11276
@NP	1 ×	11276
@NP	106 NIMSCs -LRB- n = 7 -RRB-	11279
@NP	106 NIMSCs	11279
@NP	n	11291
@NP	7	11295
@NP	group	11305
@NP	II	11311
@NP	1 × 106 OECs -LRB- n = 7 -RRB-	11315
@NP	1 × 106 OECs	11315
@NP	n	11329
@NP	7	11333
@NP	the lesion site at three points -LRB- 5 µl at each site of injection -RRB-	11355
@NP	the lesion site	11355
@NP	three points -LRB- 5 µl at each site of injection -RRB-	11374
@NP	three points	11374
@NP	5 µl at each site of injection	11388
@NP	5 µl	11388
@NP	each site of injection	11396
@NP	each site	11396
@NP	injection	11409
@NP	the third group serving as control	11424
@NP	the third group	11424
@NP	control	11451
@NP	15 µl of medium with no cells	11460
@NP	15 µl	11460
@NP	medium with no cells	11469
@NP	medium	11469
@NP	no cells	11481
@NP	n = 7	11513
@NP	n	11513
@NP	= 7	11515
@NP	muscles and skin	11529
@NP	layers	11561
@NP	the completion of transplantation procedures	11579
@NP	the completion	11579
@NP	transplantation procedures	11597
@NP	viability of the cells	11625
@NP	viability	11625
@NP	the cells	11638
@NP	another aliquot in tissue culture flask	11675
@NP	another aliquot	11675
@NP	tissue culture flask	11694
@NP	them	11727
@NP	several days	11736
@NP	2.6	11750
@NP	Behavioral assessment The recovery of gross motor function	11755
@NP	Behavioral assessment The recovery	11755
@NP	Behavioral assessment	11755
@NP	The recovery	11777
@NP	gross motor function	11793
@NP	Basso -- Beattie -- Bresnahan -LRB- BBB -RRB-	11834
@NP	Basso -- Beattie -- Bresnahan	11834
@NP	Beattie	11840
@NP	BBB	11859
@NP	locomotor rating scale on the first day post injury and once per week	11864
@NP	locomotor rating scale	11864
@NP	the first day post injury and once per week	11890
@NP	the first day post injury	11890
@NP	once per week	11920
@NP	once	11920
@NP	week	11929
@NP	five weeks after cell transplantation	11949
@NP	five weeks	11949
@NP	cell transplantation	11966
@NP	BBB rating scale	11988
@NP	a range from complete paralysis -LRB- score 0 -RRB-	12012
@NP	a range	12012
@NP	complete paralysis -LRB- score 0 -RRB-	12025
@NP	complete paralysis	12025
@NP	score 0	12045
@NP	normal gait -LRB- score 21 -RRB- -LRB- Liebert , 1995 -RRB-	12057
@NP	normal gait -LRB- score 21 -RRB-	12057
@NP	normal gait	12057
@NP	score 21	12070
@NP	Liebert	12081
@NP	1995	12090
@NP	Locomotion	12097
@NP	digital video camera at each time point	12124
@NP	digital video camera	12124
@NP	each time point	12148
@NP	two blind researchers	12180
@NP	Statistical comparison between experimental groups	12203
@NP	Statistical comparison	12203
@NP	experimental groups	12234
@NP	repeated measures	12274
@NP	analysis of variance -LRB- ANOVA -RRB-	12292
@NP	analysis	12292
@NP	variance -LRB- ANOVA -RRB-	12304
@NP	variance	12304
@NP	ANOVA	12314
@NP	Dunnett T3 analysis	12333
@NP	post hoc test	12356
@NP	SPSS version 13 -LRB- SPSS Inc. , Chicago , IL , USA -RRB-	12377
@NP	SPSS version 13	12377
@NP	SPSS Inc. , Chicago , IL , USA	12394
@NP	SPSS Inc.	12394
@NP	Chicago	12405
@NP	IL	12414
@NP	USA	12418
@NP	2.7	12424
@NP	Histological assessment Six weeks	12429
@NP	Histological assessment	12429
@NP	Six weeks	12453
@NP	injury	12469
@NP	five weeks post transplantation	12477
@NP	five weeks	12477
@NP	post transplantation	12488
@NP	all the rats	12511
@NP	70 mg/kg ketamine	12550
@NP	10 mg/kg xylazine	12569
@NP	4 % paraformaldehyde -LRB- PFA , 0.1 M , pH 7.4 -RRB-	12621
@NP	4 % paraformaldehyde	12621
@NP	PFA	12642
@NP	0.1 M	12647
@NP	pH 7.4	12654
@NP	The spinal cord	12663
@NP	overnight in 4 % PFA	12705
@NP	overnight	12705
@NP	4 % PFA	12718
@NP	4 ◦ C.	12728
@NP	4 ◦	12728
@NP	C.	12731
@NP	immunohistological analysis	12747
@NP	the spinal cord	12776
@NP	paraffin	12808
@NP	10 and 20 µm thicknesses	12849
@NP	a microtome	12878
@NP	Sections	12891
@NP	the presence of GFP positive NIMSC	12918
@NP	the presence	12918
@NP	GFP positive NIMSC	12934
@NP	anti GFP HorseRadish Peroxidase	12960
@NP	HRP	12993
@NP	antibody -LRB- 1/2000 , Abcam , USA -RRB-	13009
@NP	antibody	13009
@NP	1/2000	13019
@NP	Abcam	13027
@NP	USA	13034
@NP	the presence	13048
@NP	BrdU positive OECs	13064
@NP	anti BrdU HRP conjugated antibody -LRB- 1/2000 , AbD Serotec , USA -RRB-	13090
@NP	anti BrdU HRP	13090
@NP	antibody -LRB- 1/2000 , AbD Serotec , USA -RRB-	13115
@NP	antibody	13115
@NP	1/2000 , AbD Serotec , USA	13125
@NP	1/2000	13125
@NP	AbD Serotec , USA	13133
@NP	Samples	13152
@NP	light microscope	13180
@NP	diaminobenzidine -LRB- DAB -RRB- -LRB- Sigma , USA -RRB-	13210
@NP	diaminobenzidine -LRB- DAB -RRB-	13210
@NP	diaminobenzidine	13210
@NP	DAB	13228
@NP	Sigma	13234
@NP	USA	13241
@NP	The method of cavitation analysis	13247
@NP	The method	13247
@NP	cavitation analysis	13261
@NP	that previously described -LRB- Parr et al. , 2008 -RRB-	13308
@NP	that previously described	13308
@NP	that	13308
@NP	Parr	13335
@NP	et al. , 2008	13340
@NP	et al.	13340
@NP	2008	13348
@NP	Every eight sections from the spinal cord samples	13355
@NP	Every eight sections	13355
@NP	the spinal cord samples	13381
@NP	H&E staining	13424
@NP	The area of cavitation of each section	13438
@NP	The area	13438
@NP	cavitation of each section	13450
@NP	cavitation	13450
@NP	each section	13464
@NP	Image J software	13494
@NP	Any necrotic tissue within the cavities	13512
@NP	Any necrotic tissue	13512
@NP	the cavities	13539
@NP	part of the lesion	13567
@NP	part	13567
@NP	the lesion	13575
@NP	The total tissue area of the samples	13587
@NP	The total tissue area	13587
@NP	the samples	13612
@NP	5 mm rostral and caudal	13657
@NP	5 mm rostral	13657
@NP	caudal	13674
@NP	the injury epicenter covering a total of 1 cm of spinal cord	13684
@NP	the injury epicenter	13684
@NP	a total of 1 cm of spinal cord	13714
@NP	a total	13714
@NP	1 cm of spinal cord	13725
@NP	1 cm	13725
@NP	spinal cord	13733
@NP	The total cavity volume -LRB- Volcav -RRB-	13746
@NP	The total cavity volume	13746
@NP	Volcav	13771
@NP	total spinal cord volume -LRB- Voltotal -RRB-	13783
@NP	total spinal cord volume	13783
@NP	Voltotal	13809
@NP	the percentage of cavitation -LRB- % Volcav -RRB-	13844
@NP	the percentage	13844
@NP	cavitation -LRB- % Volcav -RRB-	13862
@NP	cavitation	13862
@NP	% Volcav	13874
@NP	the following equation : % VolCav = Volcav/Voltotal × 100 %	13911
@NP	the following equation	13911
@NP	% VolCav = Volcav/Voltotal × 100 %	13935
@NP	% VolCav = Volcav/Voltotal ×	13935
@NP	assessment of axonal density	13973
@NP	assessment	13973
@NP	axonal density	13987
@NP	sections	14003
@NP	mouse monoclonal anti neurofilament 200 kD	14036
@NP	NF-200 , 1:1000 ; Sigma , USA	14080
@NP	NF-200	14080
@NP	1:1000 ; Sigma	14088
@NP	1:1000	14088
@NP	Sigma	14096
@NP	USA	14103
@NP	HRPconjugated secondary antibody and DAB	14142
@NP	The positively intact axons	14184
@NP	five random fields at 200 × magnification	14228
@NP	five random fields	14228
@NP	200 × magnification	14250
@NP	the epicenter of injury	14272
@NP	the epicenter	14272
@NP	injury	14289
@NP	Image J software	14302
@NP	Statistical comparison between experimental groups	14320
@NP	Statistical comparison	14320
@NP	experimental groups	14351
@NP	Kruskal	14391
@NP	Wallis test	14399
@NP	appropriate post hoc test for k independent samples for the axon density values	14423
@NP	appropriate post hoc test for k independent samples	14423
@NP	k independent samples	14453
@NP	the axon density values	14479
@NP	Results Fig. 1 .	14508
@NP	Results	14508
@NP	Fig. 1	14516
@NP	Characterization of transplanted cells .	14524
@NP	Characterization	14524
@NP	transplanted cells	14544
@NP	Determination of cell surface antigens by flow cytometry -LRB- A -RRB- .	14564
@NP	Determination	14564
@NP	cell surface antigens	14581
@NP	flow cytometry -LRB- A -RRB-	14606
@NP	flow cytometry	14606
@NP	A	14622
@NP	Phase-contrast microscopic image	14626
@NP	undifferentiated MSC -LRB- B -RRB-	14662
@NP	undifferentiated MSC	14662
@NP	B	14684
@NP	adipogenic -LRB- C -RRB-	14688
@NP	adipogenic	14688
@NP	C	14700
@NP	osteogenic -LRB- D -RRB- differentiation	14707
@NP	D	14719
@NP	MSC	14741
@NP	Phase-contrast micrographs of OEC -LRB- E -RRB- .	14746
@NP	Phase-contrast micrographs	14746
@NP	OEC -LRB- E -RRB-	14776
@NP	OEC	14776
@NP	E	14781
@NP	Fluorescent images of OECs	14785
@NP	Fluorescent images	14785
@NP	OECs	14807
@NP	DAPI -LRB- F -RRB- and anti-P75 antibody -LRB- G -RRB-	14825
@NP	DAPI	14825
@NP	F	14831
@NP	anti-P75 antibody	14838
@NP	G	14857
@NP	culture purity	14871
@NP	Scale bars	14887
@NP	100 µm	14908
@NP	Fig. 2 .	14917
@NP	Fig.	14917
@NP	2	14922
@NP	Fluorescent images of GFP	14925
@NP	Fluorescent images	14925
@NP	GFP	14947
@NP	undifferentiated MSC and immunostaining of NIMSC	14959
@NP	undifferentiated MSC and immunostaining	14959
@NP	NIMSC	15002
@NP	Nuclear staining of undifferentiated MSC -LRB- A -RRB- and GFP	15009
@NP	Nuclear staining	15009
@NP	undifferentiated MSC -LRB- A -RRB- and GFP	15029
@NP	undifferentiated MSC -LRB- A -RRB-	15029
@NP	undifferentiated MSC	15029
@NP	A	15051
@NP	GFP	15058
@NP	cells -LRB- B -RRB-	15070
@NP	cells	15070
@NP	B	15077
@NP	Merged image	15081
@NP	a transduction rate of 95 % -LRB- C -RRB-	15103
@NP	a transduction rate	15103
@NP	95 % -LRB- C -RRB-	15126
@NP	95 %	15126
@NP	C	15131
@NP	Light microscopic image of NIMSC -LRB- E -RRB- , MAP-2 -LRB- F -RRB- and	15135
@NP	Light microscopic image	15135
@NP	NIMSC -LRB- E -RRB- , MAP-2 -LRB- F -RRB- and	15162
@NP	NIMSC -LRB- E -RRB-	15162
@NP	NIMSC	15162
@NP	E	15169
@NP	MAP-2 -LRB- F -RRB-	15173
@NP	MAP-2	15173
@NP	F	15180
@NP	tubulin -LRB- G -RRB- immunostaining	15189
@NP	tubulin	15189
@NP	G	15198
@NP	immunostaining	15201
@NP	Scale bars	15217
@NP	100 µm	15238
@NP	Fig. 3 .	15247
@NP	Fig.	15247
@NP	3	15252
@NP	images	15264
@NP	videos	15276
@NP	hindlimb posture in animals	15288
@NP	hindlimb posture	15288
@NP	animals	15308
@NP	cell transplantation -LRB- week 0 -RRB-	15323
@NP	cell transplantation	15323
@NP	week 0	15345
@NP	the end	15360
@NP	study -LRB- week 6 -RRB-	15371
@NP	study	15371
@NP	week 6	15378
@NP	the three studied groups	15389
@NP	the three	15389
@NP	groups	15407
@NP	control , OEC and NIMSC	15415
@NP	control	15415
@NP	OEC and NIMSC	15424
@NP	Fig. 4 .	15441
@NP	Fig.	15441
@NP	4	15446
@NP	Weekly improvements in animal hindlimb motor function during study	15449
@NP	Weekly improvements	15449
@NP	animal hindlimb motor function during study	15472
@NP	animal hindlimb motor function	15472
@NP	study	15510
@NP	BBB	15528
@NP	system	15540
@NP	Scores in NIMSC group	15548
@NP	Scores	15548
@NP	NIMSC group	15558
@NP	OEC and control group	15600
@NP	P <	15624
@NP	P	15624
@NP	<	15626
@NP	0.05	15628
@NP	OEC group	15635
@NP	a significantly higher BBB score	15659
@NP	control group -LRB- * P < 0.05 -RRB-	15697
@NP	control group	15697
@NP	P <	15713
@NP	P	15713
@NP	<	15715
@NP	0.05	15717
@NP	Data	15724
@NP	the means	15746
@NP	SD	15758
@NP	Fig. 5 .	15763
@NP	Fig.	15763
@NP	5	15768
@NP	Weekly survival diagram	15771
@NP	the dead animals	15804
@NP	the course of study	15828
@NP	the course	15828
@NP	study	15842
@NP	Fig. 6 .	15850
@NP	Fig.	15850
@NP	6	15855
@NP	Detection of the	15858
@NP	Detection	15858
@NP	the	15871
@NP	transplanted cells in the injured tissue	15883
@NP	transplanted cells	15883
@NP	the injured tissue	15905
@NP	Light microscopic images	15925
@NP	GFP positive cells -LRB- NIMSC -RRB- -LRB- A -RRB-	15953
@NP	GFP positive cells -LRB- NIMSC -RRB-	15953
@NP	GFP positive cells	15953
@NP	NIMSC	15973
@NP	A	15981
@NP	BrdU positive cells -LRB- OEC -RRB-	15988
@NP	BrdU positive cells	15988
@NP	OEC	16009
@NP	B	16015
@NP	the injured parenchyma tissue , five weeks after transplantation using HRP	16021
@NP	the injured parenchyma tissue	16021
@NP	five weeks after transplantation using HRP	16052
@NP	five weeks	16052
@NP	transplantation using HRP	16069
@NP	transplantation	16069
@NP	HRP	16091
@NP	antibody	16106
@NP	Scale bars	16116
@NP	100 µm	16137
@NP	Fig. 7 .	16146
@NP	Fig.	16146
@NP	7	16151
@NP	Light microscopic images	16154
@NP	cavity formation	16182
@NP	the three -LRB- control , OEC and NIMSC -RRB- groups -LRB- A -RRB-	16202
@NP	the three -LRB- control , OEC and NIMSC -RRB-	16202
@NP	the three	16202
@NP	control , OEC and NIMSC	16213
@NP	control	16213
@NP	OEC and NIMSC	16222
@NP	groups -LRB- A -RRB-	16237
@NP	groups	16237
@NP	A	16245
@NP	The percentage of area occupied with syrinx cavity .	16249
@NP	The percentage	16249
@NP	area occupied with syrinx cavity	16267
@NP	area	16267
@NP	syrinx cavity	16286
@NP	the OEC and NIMSC groups	16304
@NP	cavity formation	16330
@NP	the control group	16375
@NP	P <	16395
@NP	P	16395
@NP	<	16397
@NP	0.05	16399
@NP	The difference between percentage of cavitation in NIMSC and OEC groups	16406
@NP	The difference	16406
@NP	percentage of cavitation in NIMSC and OEC groups	16429
@NP	percentage	16429
@NP	cavitation in NIMSC and OEC groups	16443
@NP	cavitation	16443
@NP	NIMSC and OEC groups	16457
@NP	P > 0.05	16513
@NP	P	16513
@NP	> 0.05	16515
@NP	>	16515
@NP	0.05	16517
@NP	B	16524
@NP	Data	16528
@NP	the means	16550
@NP	SD	16562
@NP	Scale bars	16566
@NP	100 µm	16587
@NP	Fig. 8 .	16596
@NP	Fig.	16596
@NP	8	16601
@NP	Light microscopic images	16604
@NP	NF-positive axons	16637
@NP	all studied groups -LRB- control , OEC and NIMSC -RRB- -LRB- A -RRB-	16658
@NP	all	16658
@NP	groups -LRB- control , OEC and NIMSC -RRB- -LRB- A -RRB-	16670
@NP	groups -LRB- control , OEC and NIMSC -RRB-	16670
@NP	groups	16670
@NP	control , OEC and NIMSC	16678
@NP	control	16678
@NP	OEC and NIMSC	16687
@NP	A	16703
@NP	Percentage of NF-positive axons in injured area .	16707
@NP	Percentage	16707
@NP	NF-positive axons	16721
@NP	injured area	16742
@NP	NIMSC group	16756
@NP	significantly more positive axons	16772
@NP	the other two groups -LRB- * P < 0.05 -RRB-	16818
@NP	the other two groups	16818
@NP	P <	16841
@NP	P	16841
@NP	<	16843
@NP	0.05	16845
@NP	the number of NF-IR positive axons in the OEC treated group	16862
@NP	the number	16862
@NP	NF-IR positive axons in the OEC treated group	16876
@NP	NF-IR positive axons	16876
@NP	the OEC treated group	16900
@NP	the OEC	16900
@NP	group	16916
@NP	the control group -LRB- * P < 0.05 -RRB- -LRB- B -RRB-	16953
@NP	the control group -LRB- * P < 0.05 -RRB-	16953
@NP	the control group	16953
@NP	P <	16973
@NP	P	16973
@NP	<	16975
@NP	0.05	16977
@NP	B	16984
@NP	Data	16988
@NP	the means	17010
@NP	S.D.	17022
@NP	Scale bars	17027
@NP	100 µm	17048
@NP	3.1	17057
@NP	MSCs and OECs	17062
@NP	characterization Surface markers of fibroblast-like cells	17076
@NP	characterization Surface markers	17076
@NP	fibroblast-like cells	17112
@NP	bone marrow	17148
@NP	flowcytometry analysis	17180
@NP	Data	17204
@NP	the expression of cell surface antigens such as CD90 and CD73	17221
@NP	the expression	17221
@NP	cell surface antigens such as CD90 and CD73	17239
@NP	cell surface antigens	17239
@NP	CD90 and CD73	17269
@NP	they	17303
@NP	negative for CD31 , CD44 , CD45 -LRB- Fig. 1A -RRB-	17313
@NP	negative for CD31 , CD44 , CD45	17313
@NP	CD31 , CD44 ,	17326
@NP	CD31	17326
@NP	CD44	17332
@NP	Fig. 1A	17344
@NP	The formation	17354
@NP	oil droplets and calcium depositions stained with Oil Red O and Alizarin Red	17371
@NP	oil droplets and calcium depositions	17371
@NP	Oil Red O and Alizarin Red	17421
@NP	the multilineage differentiation potential	17472
@NP	the isolated mesenchymal cells -LRB- Fig. 1B -- D -RRB-	17518
@NP	the isolated mesenchymal cells	17518
@NP	Fig. 1B -- D	17550
@NP	Fig. 1B	17550
@NP	D	17558
@NP	OECs present low affinity NGF receptor -LRB- P75 -RRB- on their cell surfaces .	17562
@NP	OECs	17562
@NP	present low affinity NGF receptor -LRB- P75 -RRB- on their cell surfaces	17567
@NP	present low affinity NGF receptor -LRB- P75 -RRB-	17567
@NP	present low affinity NGF receptor	17567
@NP	P75	17602
@NP	their cell surfaces	17610
@NP	the purification of the enriched population	17641
@NP	the purification	17641
@NP	the enriched population	17661
@NP	cells	17686
@NP	anti-P75 antibody	17710
@NP	Merged images	17729
@NP	majority of the cells -LRB- > 95 % -RRB-	17755
@NP	majority	17755
@NP	the cells -LRB- > 95 % -RRB-	17767
@NP	the cells	17767
@NP	> 95 %	17778
@NP	>	17778
@NP	95 %	17779
@NP	this marker -LRB- Fig. 1E -- G -RRB-	17802
@NP	this marker	17802
@NP	Fig. 1E -- G	17815
@NP	Fig. 1E	17815
@NP	G	17823
@NP	MSCs	17840
@NP	cells	17846
@NP	GFP bearing lentiviral vectors	17873
@NP	Percentage of tranduced cells	17905
@NP	Percentage	17905
@NP	tranduced cells	17919
@NP	fluorescent microscope and DAPI nuclear staining	17956
@NP	fluorescent microscope	17956
@NP	DAPI nuclear staining	17983
@NP	more	18014
@NP	than75 % of the cells to be positive for GFP -LRB- Fig. 2A -- C -RRB-	18019
@NP	than75 %	18019
@NP	the cells	18030
@NP	GFP	18059
@NP	Fig. 2A -- C	18064
@NP	Fig. 2A	18064
@NP	C	18072
@NP	3.2	18076
@NP	NIMSCs characterization	18081
@NP	the MSCs	18116
@NP	neural lineage	18132
@NP	their morphology	18147
@NP	a day	18187
@NP	The cells	18194
@NP	characteristic round cell bodies	18214
@NP	several branching extensions	18252
@NP	Approximately 30 % of the cell population	18282
@NP	Approximately 30 %	18282
@NP	the cell population	18303
@NP	shape	18352
@NP	contact	18379
@NP	neighboring cells	18392
@NP	7 days of culture in neurogenic media	18417
@NP	7 days	18417
@NP	culture in neurogenic media	18427
@NP	culture	18427
@NP	neurogenic media	18438
@NP	the cells	18456
@NP	neural markers	18484
@NP	MAP2	18500
@NP	beta-tubulin III	18509
@NP	the production of these neural cytoskeletal proteins	18541
@NP	the production	18541
@NP	these neural cytoskeletal proteins	18559
@NP	the differentiated cells	18597
@NP	the	18597
@NP	cells	18616
@NP	Fig. 2D -- F	18623
@NP	Fig. 2D	18623
@NP	F	18631
@NP	We	18635
@NP	neurally induced rat MSCs	18664
@NP	immature -LRB- Nestin and beta-tubulin III -RRB-	18703
@NP	immature	18703
@NP	Nestin and beta-tubulin III	18713
@NP	Nestin	18713
@NP	beta-tubulin III	18724
@NP	mature -LRB- NSE and MAP2 -RRB- neuronal markers	18746
@NP	NSE and MAP2	18754
@NP	NSE	18754
@NP	MAP2	18762
@NP	not glial markers -LRB- GFAP -RRB- -LRB- Pedram et al. , 2009 -RRB-	18789
@NP	not glial markers -LRB- GFAP -RRB-	18789
@NP	not glial markers	18789
@NP	GFAP	18808
@NP	Pedram	18815
@NP	et al. , 2009	18822
@NP	et al.	18822
@NP	2009	18830
@NP	3.3	18837
@NP	Functional improvements	18842
@NP	We	18866
@NP	the recovery	18878
@NP	hindlimb function	18894
@NP	BBB scale , in which the maximum hindlimb motor function score was 21	18918
@NP	BBB scale	18918
@NP	the maximum hindlimb motor function score	18938
@NP	the maximum hindlimb	18938
@NP	motor function score	18959
@NP	21	18984
@NP	All rats	18988
@NP	a score of 21	19001
@NP	a score	19001
@NP	21	19012
@NP	the injury	19029
@NP	the scores	19044
@NP	0 -- 1 soon after the compression	19071
@NP	0 -- 1	19071
@NP	the compression	19086
@NP	We	19103
@NP	OECs , NIMSCs or pure medium	19119
@NP	OECs	19119
@NP	NIMSCs	19125
@NP	pure medium	19135
@NP	the spinal cord 7 days	19152
@NP	the spinal cord	19152
@NP	7 days	19168
@NP	injury	19181
@NP	the rats subjected to contusion and then injected with NIMSCs	19192
@NP	the rats	19192
@NP	contusion	19214
@NP	NIMSCs	19247
@NP	BBB score	19255
@NP	14.25	19278
@NP	± 1.69	19284
@NP	a five week interval	19295
@NP	the time of transplantation	19321
@NP	the time	19321
@NP	transplantation	19333
@NP	this score	19355
@NP	8.625	19370
@NP	± 1.03	19376
@NP	the OEC treated group and 7.375 ± 0.916 in the control ones	19386
@NP	the OEC	19386
@NP	group and 7.375 ± 0.916	19402
@NP	group	19402
@NP	7.375 ± 0.916	19412
@NP	7.375	19412
@NP	± 0.916	19418
@NP	the control ones	19429
@NP	functional terms	19450
@NP	the contused rats in NIMSC group	19468
@NP	the contused rats	19468
@NP	NIMSC group	19489
@NP	consistent weight	19517
@NP	plantar steps	19545
@NP	forelimb and hindlimb coordination	19564
@NP	rats in OEC treated group	19611
@NP	rats	19611
@NP	OEC treated group	19619
@NP	no weigh support	19656
@NP	rats in the control group	19683
@NP	rats	19683
@NP	the control group	19691
@NP	all three joint	19720
@NP	they	19749
@NP	sweep	19773
@NP	planter step -LRB- Fig. 3 , Supplementary videos 1 -- 6 -RRB-	19785
@NP	planter step	19785
@NP	Fig. 3 , Supplementary videos 1 -- 6	19799
@NP	Fig. 3 , Supplementary videos	19799
@NP	Fig. 3	19799
@NP	Supplementary videos	19807
@NP	1 -- 6	19828
@NP	The improvement of locomotor function in NIMSC group	19834
@NP	The improvement	19834
@NP	locomotor function in NIMSC group	19853
@NP	locomotor function	19853
@NP	NIMSC group	19875
@NP	OEC and control groups	19917
@NP	P < 0.05	19941
@NP	P	19941
@NP	< 0.05	19943
@NP	<	19943
@NP	0.05	19945
@NP	OEC group	19963
@NP	a significantly higher BBB score	19987
@NP	control group	20025
@NP	five weeks -LRB- P < 0.05 -RRB- -LRB- Fig. 4 -RRB-	20045
@NP	five weeks -LRB- P < 0.05 -RRB-	20045
@NP	P < 0.05	20057
@NP	P	20057
@NP	< 0.05	20059
@NP	<	20059
@NP	0.05	20061
@NP	Fig. 4	20068
@NP	all groups	20094
@NP	most of the locomotor function improvements	20106
@NP	most	20106
@NP	the locomotor function improvements	20114
@NP	the first week	20166
@NP	The control and treated groups	20182
@NP	The control	20182
@NP	treated groups	20198
@NP	a steady recovery	20223
@NP	the fifth week , which was the end point of the experiment -LRB- Fig. 4 -RRB-	20282
@NP	the fifth week	20282
@NP	the end point of the experiment -LRB- Fig. 4 -RRB-	20308
@NP	the end point	20308
@NP	the experiment -LRB- Fig. 4 -RRB-	20325
@NP	the experiment	20325
@NP	Fig. 4	20341
@NP	3.4	20350
@NP	Mortality rate of animals Rate of mortality in cell treated groups	20355
@NP	Mortality rate	20355
@NP	animals Rate of mortality in cell treated groups	20373
@NP	animals Rate	20373
@NP	mortality in cell treated groups	20389
@NP	mortality	20389
@NP	cell treated groups	20402
@NP	control group	20441
@NP	the first and second week post transplantation	20467
@NP	2 rats	20514
@NP	the control group	20531
@NP	each week	20552
@NP	the course of follow up in the NIMSC treated group no rat	20577
@NP	the course	20577
@NP	the NIMSC treated group no rat	20604
@NP	the NIMSC	20604
@NP	group	20622
@NP	no rat	20628
@NP	the OEC treated group	20643
@NP	the OEC	20643
@NP	group	20659
@NP	only one rat	20665
@NP	the first week -LRB- Fig. 5 -RRB-	20686
@NP	the first week	20686
@NP	Fig. 5	20702
@NP	addition	20714
@NP	the end of the study rats	20751
@NP	the end	20751
@NP	the study rats	20762
@NP	cell treatment	20787
@NP	a better hygiene and health status	20806
@NP	a better hygiene	20806
@NP	health status	20827
@NP	the control group -LRB- not shown -RRB-	20846
@NP	the control group	20846
@NP	3.5	20877
@NP	transplanted cells	20890
@NP	tissue	20912
@NP	Five weeks	20919
@NP	transplantation	20936
@NP	paraffin-embedded tissue sections	20953
@NP	GFP	21011
@NP	BrdU stained cells using HRP conjugated secondary antibody against GFP and BrdU	21028
@NP	BrdU	21028
@NP	cells	21041
@NP	HRP	21053
@NP	secondary antibody	21068
@NP	GFP and BrdU	21095
@NP	GFP	21095
@NP	BrdU	21103
@NP	The positive cells	21109
@NP	the parenchyma of the analyzed tissues -LRB- Fig. 6 -RRB-	21152
@NP	the parenchyma	21152
@NP	the analyzed tissues -LRB- Fig. 6 -RRB-	21170
@NP	the analyzed tissues	21170
@NP	Fig. 6	21192
@NP	3.6	21201
@NP	Cavitation analysis The percentage of cavitation	21206
@NP	Cavitation analysis The percentage	21206
@NP	Cavitation analysis	21206
@NP	The percentage	21226
@NP	cavitation	21244
@NP	H&E staining -LRB- Fig. 7A -RRB-	21276
@NP	H&E staining	21276
@NP	Fig. 7A	21290
@NP	Data	21300
@NP	cavitation area	21317
@NP	NIMSC and OEC treated groups	21359
@NP	NIMSC	21359
@NP	OEC treated groups	21369
@NP	comparison with control group -LRB- P < 0.05 -RRB-	21391
@NP	comparison	21391
@NP	control group -LRB- P < 0.05 -RRB-	21407
@NP	control group	21407
@NP	P < 0.05	21422
@NP	P	21422
@NP	< 0.05	21424
@NP	<	21424
@NP	0.05	21426
@NP	the percentage of cavitaion in NIMSC treated group	21442
@NP	the percentage	21442
@NP	cavitaion in NIMSC treated group	21460
@NP	cavitaion	21460
@NP	NIMSC treated group	21473
@NP	a slight decrease	21500
@NP	OEC group but this difference	21530
@NP	OEC group	21530
@NP	this difference	21544
@NP	P > 0.05	21595
@NP	P	21595
@NP	> 0.05	21597
@NP	>	21597
@NP	0.05	21599
@NP	Fig. 7B	21606
@NP	3.7	21616
@NP	Axonal regeneration	21621
@NP	We	21641
@NP	HRP	21649
@NP	anti-neurofilament antibody	21664
@NP	axonal density -LRB- Fig. 8A -RRB-	21704
@NP	axonal density	21704
@NP	Fig. 8A	21720
@NP	The number of NF-immunoreactive -LRB- IR -RRB- axons	21730
@NP	The number	21730
@NP	NF-immunoreactive -LRB- IR -RRB- axons	21744
@NP	IR	21763
@NP	NIMSC treated groups	21801
@NP	OEC treated and control groups -LRB- P < 0.05 -RRB-	21834
@NP	OEC treated	21834
@NP	OEC	21834
@NP	control groups -LRB- P < 0.05 -RRB-	21850
@NP	control groups	21850
@NP	P < 0.05	21866
@NP	P	21866
@NP	< 0.05	21868
@NP	<	21868
@NP	0.05	21870
@NP	the number of NF-IR positive axons in the OEC treated group	21887
@NP	the number	21887
@NP	NF-IR positive axons in the OEC treated group	21901
@NP	NF-IR positive axons	21901
@NP	the OEC treated group	21925
@NP	the OEC	21925
@NP	group	21941
@NP	the control group -LRB- P < 0.05 -RRB- -LRB- Fig. 8B -RRB-	21978
@NP	the control group -LRB- P < 0.05 -RRB-	21978
@NP	the control group	21978
@NP	P < 0.05	21997
@NP	P	21997
@NP	< 0.05	21999
@NP	<	21999
@NP	0.05	22001
@NP	Fig. 8B	22008
@NP	Discussion The present study	22022
@NP	Discussion	22022
@NP	The present study	22033
@NP	the capacity of differentiation of BMSCs	22061
@NP	the capacity	22061
@NP	differentiation of BMSCs	22077
@NP	differentiation	22077
@NP	BMSCs	22096
@NP	neuron	22107
@NP	cells and ability of these cells	22119
@NP	cells and ability	22119
@NP	these cells	22140
@NP	SCI in both behavioral and histological aspects	22163
@NP	SCI	22163
@NP	both behavioral and histological aspects	22170
@NP	great promises	22220
@NP	the translation of MSC research	22239
@NP	the translation	22239
@NP	MSC research	22258
@NP	the clinics	22276
@NP	Our results	22289
@NP	better outcomes	22308
@NP	NIMSC	22333
@NP	OECs	22344
@NP	This work	22350
@NP	continuation	22367
@NP	our previous study	22383
@NP	we	22411
@NP	rat	22435
@NP	SCI model , neurally	22439
@NP	SCI model	22439
@NP	MSCs	22467
@NP	far better outcomes	22488
@NP	terms of behavioral improvements	22511
@NP	terms	22511
@NP	behavioral improvements	22520
@NP	non induced MSCs	22556
@NP	Pedram	22574
@NP	et al. , 2009	22581
@NP	et al.	22581
@NP	2009	22589
@NP	Our results	22596
@NP	the enormous capacity of NIMSC	22620
@NP	the enormous capacity	22620
@NP	NIMSC	22645
@NP	the injured tissue	22665
@NP	their role	22695
@NP	the cavitation	22718
@NP	axonal growth	22747
@NP	motor performance	22788
@NP	some outcomes that were not achieved to the same extent by OEC	22807
@NP	some outcomes	22807
@NP	the same extent	22847
@NP	OEC	22866
@NP	Several methods	22871
@NP	about spinal damage	22911
@NP	animal models	22934
@NP	this study	22952
@NP	we	22964
@NP	the pressure method	22977
@NP	Fogarty catheter	23003
@NP	The best injury models for spinal regeneration by cell therapy	23021
@NP	The best injury models	23021
@NP	spinal regeneration by cell therapy	23048
@NP	spinal regeneration	23048
@NP	cell therapy	23071
@NP	those showing improvement over time	23088
@NP	those showing improvement	23088
@NP	time	23119
@NP	Vanicky et al.	23125
@NP	Vanicky	23125
@NP	et al.	23133
@NP	this much of pressure per weight of rats	23183
@NP	this much	23183
@NP	pressure per weight of rats	23196
@NP	pressure	23196
@NP	weight of rats	23209
@NP	weight	23209
@NP	rats	23219
@NP	some degrees of improvement	23225
@NP	some degrees	23225
@NP	improvement	23241
@NP	time	23270
@NP	They	23276
@NP	five weeks of damage	23302
@NP	five weeks	23302
@NP	damage	23316
@NP	the score	23323
@NP	0 -- 1 to about 8.5 -LRB- Vanicky ' et al. , 2001 -RRB-	23352
@NP	0 -- 1	23352
@NP	about 8.5 -LRB- Vanicky ' et al. , 2001 -RRB-	23359
@NP	about 8.5	23359
@NP	Vanicky ' et al. , 2001	23370
@NP	Vanicky '	23370
@NP	et al.	23379
@NP	2001	23387
@NP	our study , five weeks post transplantation	23397
@NP	our study	23397
@NP	five weeks post transplantation	23408
@NP	five weeks	23408
@NP	the score of control group	23440
@NP	the score	23440
@NP	control group	23453
@NP	7.3 , which is pretty close to the result mentioned in study of Vanicky et al.	23484
@NP	7.3	23484
@NP	the result	23514
@NP	study of Vanicky	23538
@NP	study	23538
@NP	Vanicky	23547
@NP	et al.	23555
@NP	This lower value	23562
@NP	variations between animals	23595
@NP	variations	23595
@NP	animals	23614
@NP	reoperation and negligible damage	23623
@NP	reoperation	23623
@NP	negligible damage	23639
@NP	the time of medium injection	23667
@NP	the time	23667
@NP	medium injection	23679
@NP	Changes	23697
@NP	the CNS microenvironment	23718
@NP	a lesion	23749
@NP	namely release of inhibitory molecules from the central myelin	23759
@NP	namely release	23759
@NP	inhibitory molecules from the central myelin	23777
@NP	inhibitory molecules	23777
@NP	the central myelin	23803
@NP	proteoglycans associated with astroglial scarring	23833
@NP	proteoglycans	23833
@NP	astroglial scarring	23863
@NP	the spontaneous reorganization of the neural pathways	23890
@NP	the spontaneous reorganization	23890
@NP	the neural pathways	23924
@NP	effective regeneration -LRB- Camand et al. , 2004 ; Yiu and He , 2006 -RRB-	23956
@NP	effective regeneration	23956
@NP	Camand et al. , 2004 ; Yiu and He , 2006	23980
@NP	Camand et al.	23980
@NP	Camand	23980
@NP	et al.	23987
@NP	2004 ; Yiu	23995
@NP	2004	23995
@NP	Yiu	24001
@NP	He , 2006	24009
@NP	He	24009
@NP	2006	24013
@NP	Cell	24020
@NP	therapies	24031
@NP	SCI	24061
@NP	histological and functional outcomes	24076
@NP	two different ways	24116
@NP	by	24140
@NP	differentiation and functional integration	24143
@NP	neuron-like or oligodendrocyte-like cells	24189
@NP	the spared spinal cord circuitry -LRB- replacement approach -RRB-	24236
@NP	the spared spinal cord circuitry	24236
@NP	replacement approach	24270
@NP	host cellular or axonal survival or decreasing host	24311
@NP	host cellular or axonal survival	24311
@NP	decreasing host	24347
@NP	regeneration or remyelination of injured axons	24392
@NP	regeneration or remyelination	24392
@NP	injured axons	24425
@NP	neuromodulatory transmitters -LRB- regenerative approach -RRB-	24447
@NP	neuromodulatory transmitters	24447
@NP	regenerative approach	24477
@NP	Cummings	24501
@NP	et al. , 2005	24510
@NP	et al.	24510
@NP	2005	24518
@NP	Stem cells	24525
@NP	lost cells	24548
@NP	neuroprotection and permissive neurotrophic factors and substrates	24575
@NP	axonal regeneration	24646
@NP	transplantation	24672
@NP	the injured central nervous system	24693
@NP	Novikova	24729
@NP	et al. , 2011a ; Reier , 2004	24738
@NP	et al.	24738
@NP	2011a ; Reier	24746
@NP	2011a	24746
@NP	Reier	24753
@NP	2004	24760
@NP	Many studies	24767
@NP	a population of progenitor cells	24804
@NP	a population	24804
@NP	progenitor cells	24820
@NP	the spinal damaged tissue	24855
@NP	they	24882
@NP	environmental stimuli	24904
@NP	glial cells	24949
@NP	neurons -LRB- Castro et al. , 2002 -RRB-	24971
@NP	neurons	24971
@NP	Castro	24980
@NP	et al. , 2002	24987
@NP	et al.	24987
@NP	2002	24995
@NP	Li et al.	25002
@NP	Li	25002
@NP	et al.	25005
@NP	nestin	25019
@NP	positive precursor cells in outer-root sheath of hair follicles and Amoh et al.	25026
@NP	positive precursor cells	25026
@NP	outer-root sheath of hair follicles and Amoh et al.	25054
@NP	outer-root sheath of hair follicles	25054
@NP	outer-root sheath	25054
@NP	hair follicles	25075
@NP	Amoh et al.	25094
@NP	Amoh	25094
@NP	et al.	25099
@NP	these cells	25124
@NP	neurons , glia , keratinocytes , smooth muscle cells , and melanocytes	25159
@NP	neurons	25159
@NP	glia	25168
@NP	keratinocytes	25174
@NP	smooth muscle cells	25189
@NP	melanocytes	25214
@NP	Amoh	25236
@NP	et al. , 2005b ; Li et al. , 2003	25241
@NP	et al.	25241
@NP	2005b ; Li et al.	25249
@NP	2005b	25249
@NP	Li et al.	25256
@NP	Li	25256
@NP	et al.	25259
@NP	2003	25267
@NP	They	25274
@NP	hair follicle stem cells transplanted into sciatic injured nerve	25286
@NP	hair follicle stem cells	25286
@NP	sciatic injured nerve	25329
@NP	spinal cord lesion , largely transdifferentiate to schwann cells ,	25355
@NP	spinal cord lesion	25355
@NP	schwann cells	25405
@NP	the rate of nerve regeneration	25428
@NP	the rate	25428
@NP	nerve regeneration	25440
@NP	the sciatic nerve and spinal cord function	25471
@NP	Amoh	25515
@NP	et al. , 2005a , 2008	25520
@NP	et al.	25520
@NP	2005a	25528
@NP	2008	25535
@NP	bulge area	25551
@NP	origin	25578
@NP	these nestin-expressing pluripotent stem cells	25588
@NP	Uchugonova	25636
@NP	et al. , 2011a	25647
@NP	et al.	25647
@NP	2011a	25655
@NP	induction	25674
@NP	stem cells before transplantation or using neural restricted progenitor cells	25687
@NP	stem cells before transplantation	25687
@NP	stem cells	25687
@NP	transplantation	25705
@NP	neural restricted progenitor cells	25730
@NP	a useful method	25788
@NP	neuron replacement	25808
@NP	the injured CNS	25830
@NP	Lepore et al. , 2004 ; Lu et al. , 2006 ; Ye et al. , 2007	25847
@NP	Lepore	25847
@NP	et al. , 2004 ; Lu et al. , 2006 ; Ye et al. , 2007	25854
@NP	et al. , 2004	25854
@NP	et al.	25854
@NP	2004	25862
@NP	Lu et al. , 2006	25868
@NP	Lu	25868
@NP	et al. , 2006	25871
@NP	et al.	25871
@NP	2006	25879
@NP	Ye et al. , 2007	25885
@NP	Ye	25885
@NP	et al. , 2007	25888
@NP	et al.	25888
@NP	2007	25896
@NP	Useful effects	25903
@NP	neurally pre-differentiated embryonic and neural restricted stem cells	25921
@NP	spinal cord regeneration	25995
@NP	previous studies -LRB- Han et al. , 2002 ; Marques et al. , 2010 -RRB-	26049
@NP	previous studies	26049
@NP	Han	26067
@NP	et al. , 2002 ; Marques et al. , 2010	26071
@NP	et al.	26071
@NP	2002 ; Marques et al.	26079
@NP	2002	26079
@NP	Marques et al.	26085
@NP	Marques	26085
@NP	et al.	26093
@NP	2010	26101
@NP	Lu et al.	26108
@NP	Lu	26108
@NP	et al.	26111
@NP	the efficacy of pre-differentiated adult bone marrow cells	26132
@NP	the efficacy	26132
@NP	pre-differentiated adult bone marrow cells	26148
@NP	functional recovery	26194
@NP	rats following traumatic brain injury -LRB- Lu et al. , 2006 -RRB-	26217
@NP	rats	26217
@NP	traumatic brain injury -LRB- Lu et al. , 2006 -RRB-	26232
@NP	traumatic brain injury	26232
@NP	Lu	26256
@NP	et al. , 2006	26259
@NP	et al.	26259
@NP	2006	26267
@NP	Lin et al.	26274
@NP	Lin	26274
@NP	et al.	26278
@NP	schwann cells and neurons	26292
@NP	rat hair follicle	26342
@NP	neural crest stem cell	26360
@NP	the nerve constructs as long as eight weeks	26400
@NP	the nerve constructs	26449
@NP	desirable electrophysiological features -LRB- Lin et al. , 2011 -RRB-	26477
@NP	desirable electrophysiological features	26477
@NP	Lin	26518
@NP	et al. , 2011	26522
@NP	et al.	26522
@NP	2011	26530
@NP	Our observations	26537
@NP	neurally induced MSCs	26569
@NP	neuronal morphologic characteristics	26601
@NP	small , refractile somata	26648
@NP	multiple long processes	26674
@NP	expression of neuron specific markers -LRB- MAP2 and beta-tubulin -RRB-	26707
@NP	expression	26707
@NP	neuron specific markers -LRB- MAP2 and beta-tubulin -RRB-	26721
@NP	neuron specific markers	26721
@NP	MAP2 and beta-tubulin	26746
@NP	MAP2	26746
@NP	beta-tubulin	26755
@NP	a short term in vitro induction	26775
@NP	short term	26777
@NP	An important issue in cell based therapy	26808
@NP	An important issue	26808
@NP	cell based therapy	26830
@NP	cell	26830
@NP	therapy	26841
@NP	the survival of the grafted cells	26852
@NP	the survival	26852
@NP	the grafted cells	26868
@NP	injection	26894
@NP	we	26905
@NP	OECs	26916
@NP	BrdU	26927
@NP	them	26949
@NP	the target tissue	26957
@NP	the end of study	26978
@NP	the end	26978
@NP	study	26989
@NP	GFP labeled NIMSCs	27006
@NP	GFP	27006
@NP	NIMSCs	27018
@NP	the injured tissue	27046
@NP	the ability of these cells	27074
@NP	the ability	27074
@NP	these cells	27089
@NP	the spinal tissue of recipient rats	27119
@NP	the spinal tissue	27119
@NP	recipient rats	27140
@NP	New methods of noninvasive long-term in vivo tracking of intra-tissue stem cells	27156
@NP	New methods	27156
@NP	noninvasive long-term in vivo tracking of intra-tissue stem cells	27171
@NP	noninvasive long-term	27171
@NP	tracking of intra-tissue stem cells	27201
@NP	tracking	27201
@NP	intra-tissue stem cells	27213
@NP	long-term fate of transplanted cells -LRB- Uchugonova et al. , 2011b -RRB-	27263
@NP	long-term fate	27263
@NP	transplanted cells -LRB- Uchugonova et al. , 2011b -RRB-	27281
@NP	transplanted cells	27281
@NP	Uchugonova	27301
@NP	et al. , 2011b	27312
@NP	et al.	27312
@NP	2011b	27320
@NP	The role and function	27328
@NP	cells in functional and behavioral improvements of spinal cord injuries	27368
@NP	cells	27368
@NP	functional and behavioral improvements of spinal cord injuries	27377
@NP	functional and behavioral improvements	27377
@NP	spinal cord injuries	27419
@NP	the grafted cells ' processes	27468
@NP	the grafted cells '	27468
@NP	synaptic connections	27504
@NP	the processes of endogenous neurons -LRB- Lepore et al. , 2006 -RRB-	27530
@NP	the processes	27530
@NP	endogenous neurons -LRB- Lepore et al. , 2006 -RRB-	27547
@NP	endogenous neurons	27547
@NP	Lepore	27567
@NP	et al. , 2006	27574
@NP	et al.	27574
@NP	2006	27582
@NP	Other studies	27589
@NP	neuronal differentiation	27614
@NP	synapse formation	27640
@NP	electrophysiological connectivity	27662
@NP	transplantation	27702
@NP	neural precursor cells	27721
@NP	Auerbach et al. , 2000 ; Cummings et al. , 2005 ; Wernig et al. , 2004	27745
@NP	Auerbach	27745
@NP	et al. , 2000 ; Cummings et al. , 2005 ; Wernig et al. , 2004	27754
@NP	et al. , 2000	27754
@NP	et al.	27754
@NP	2000	27762
@NP	Cummings et al. , 2005	27768
@NP	Cummings	27768
@NP	et al. , 2005	27777
@NP	et al.	27777
@NP	2005	27785
@NP	Wernig et al. , 2004	27791
@NP	Wernig	27791
@NP	et al. , 2004	27798
@NP	et al.	27798
@NP	2004	27806
@NP	Another important possible cause	27813
@NP	axonal density and better functional outcome	27865
@NP	axonal density	27865
@NP	better functional outcome	27884
@NP	neurally induced stem	27913
@NP	the MSCs	27954
@NP	neurotrophic factors	27977
@NP	axonal growth	28024
@NP	surviving neurons	28041
@NP	rescue axons	28067
@NP	Wallerian degeneration	28085
@NP	injury -LRB- Novikova et al. , 2011a -RRB-	28114
@NP	injury	28114
@NP	Novikova	28122
@NP	et al. , 2011a	28131
@NP	et al.	28131
@NP	2011a	28139
@NP	It	28147
@NP	the synaptic connections , secretion of neurotrophic factors	28172
@NP	the synaptic connections	28172
@NP	secretion of neurotrophic factors	28198
@NP	secretion	28198
@NP	neurotrophic factors	28211
@NP	growth factor alfa -LRB- TGF-alfa -RRB-	28255
@NP	growth factor alfa	28255
@NP	TGF-alfa	28275
@NP	brain-derived neurotrophic factor -LRB- BDNF -RRB-	28289
@NP	brain-derived neurotrophic factor	28289
@NP	BDNF	28324
@NP	transplanted	28336
@NP	cells	28364
@NP	functional recovery -LRB- Kerr et al. , 2003 -RRB-	28390
@NP	functional recovery	28390
@NP	Kerr	28411
@NP	et al. , 2003	28416
@NP	et al.	28416
@NP	2003	28424
@NP	Improvement in functional results	28431
@NP	Improvement	28431
@NP	functional results	28446
@NP	this fact	28479
@NP	grafted stem cells	28494
@NP	increased survival of neurons and axons	28525
@NP	increased survival	28525
@NP	neurons and axons	28547
@NP	formation of new connections -LRB- Cummings et al. , 2005 -RRB-	28569
@NP	formation	28569
@NP	new connections -LRB- Cummings et al. , 2005 -RRB-	28582
@NP	new connections	28582
@NP	Cummings	28599
@NP	et al. , 2005	28608
@NP	et al.	28608
@NP	2005	28616
@NP	Immunomodulatory impressions of MSCs in the injured tissue	28623
@NP	Immunomodulatory impressions	28623
@NP	MSCs in the injured tissue	28655
@NP	MSCs	28655
@NP	the injured tissue	28663
@NP	one	28689
@NP	the reasons	28696
@NP	neurons and axons	28712
@NP	transplantation	28748
@NP	Caplan	28765
@NP	2007	28773
@NP	Injection of OEC	28780
@NP	Injection	28780
@NP	OEC	28793
@NP	significant improvement	28804
@NP	the BBB score compared to control group	28831
@NP	the BBB score	28831
@NP	group	28865
@NP	addition	28875
@NP	axon density in OEC group	28885
@NP	axon density	28885
@NP	OEC group	28901
@NP	control group	28942
@NP	Previous studies	28957
@NP	OECs	28986
@NP	several neurotrophic factors	29000
@NP	stromal cell	29037
@NP	factor 1-alpha -LRB- SDF-1-alfa -RRB-	29058
@NP	factor 1-alpha	29058
@NP	SDF-1-alfa	29074
@NP	BDNF	29090
@NP	trophic support	29113
@NP	injured neurons , angiogenesis , axonal remyelination and enhancement	29133
@NP	axonal regeneration	29204
@NP	Chiu	29225
@NP	et al. , 2009 ; Kocsis et al. , 2009	29230
@NP	et al.	29230
@NP	2009 ; Kocsis et al.	29238
@NP	2009	29238
@NP	Kocsis et al.	29244
@NP	Kocsis	29244
@NP	et al.	29251
@NP	2009	29259
@NP	some studies	29275
@NP	injection of OEC	29303
@NP	injection	29303
@NP	OEC	29316
@NP	spinal repair in animal model -LRB- Takami et al. , 2002 -RRB-	29344
@NP	spinal repair	29344
@NP	animal model -LRB- Takami et al. , 2002 -RRB-	29361
@NP	animal model	29361
@NP	Takami	29375
@NP	et al. , 2002	29382
@NP	et al.	29382
@NP	2002	29390
@NP	most of them	29397
@NP	most	29397
@NP	them	29405
@NP	these cells	29422
@NP	a good choice	29438
@NP	spinal regeneration -LRB- López Vales et al. , 2007 ; Verdú et al. , 2003 -RRB-	29456
@NP	spinal regeneration	29456
@NP	López Vales	29477
@NP	et al. , 2007 ; Verdú et al. , 2003	29489
@NP	et al.	29489
@NP	2007 ; Verdú et al.	29497
@NP	2007	29497
@NP	Verdú et al.	29503
@NP	Verdú	29503
@NP	et al.	29509
@NP	2003	29517
@NP	The discrepancy in results	29524
@NP	The discrepancy	29524
@NP	results	29543
@NP	many factors including variations in culture protocols	29574
@NP	many factors	29574
@NP	variations in culture protocols	29597
@NP	variations	29597
@NP	culture protocols	29611
@NP	one recent work Novikova et al.	29633
@NP	one recent work	29633
@NP	Novikova et al.	29649
@NP	Novikova	29649
@NP	et al.	29658
@NP	OECs	29675
@NP	short term -LRB- three weeks -RRB- and long term -LRB- seven weeks -RRB-	29693
@NP	short term -LRB- three weeks -RRB-	29693
@NP	short term	29693
@NP	three weeks	29705
@NP	long term -LRB- seven weeks -RRB-	29722
@NP	long term	29722
@NP	seven weeks	29733
@NP	cultures	29755
@NP	short term	29780
@NP	OEC cultures	29800
@NP	regrowth of rubrospinal , raphaespinal and CGRP positive fibers	29827
@NP	regrowth	29827
@NP	rubrospinal , raphaespinal and CGRP positive fibers	29839
@NP	CGRP	29869
@NP	significant neuroprotection	29903
@NP	axotomized rubrospinal neurons -LRB- Novikova et al. , 2011b -RRB-	29935
@NP	axotomized rubrospinal neurons	29935
@NP	Novikova	29967
@NP	et al. , 2011b	29976
@NP	et al.	29976
@NP	2011b	29984
@NP	our experiment	29995
@NP	OECs	30011
@NP	25 days	30056
@NP	the animals	30105
@NP	such short term	30124
@NP	cultures	30149
@NP	the desired result in our study	30170
@NP	the desired result	30170
@NP	our study	30192
@NP	further this work	30206
@NP	we	30225
@NP	simultaneous injection of OECs and NIMSCs	30254
@NP	simultaneous injection	30254
@NP	OECs and NIMSCs	30280
@NP	spinal cord regeneration	30300
@NP	there	30335
@NP	any synergistic effect	30344
@NP	the two types of cells tested in this work , on each own	30375
@NP	the two types	30375
@NP	cells tested in this work , on each own	30392
@NP	cells	30392
@NP	this work	30408
@NP	each own	30422
@NP	regard	30437
@NP	different capacities of these cells	30447
@NP	different capacities	30447
@NP	these cells	30471
@NP	different mechanisms through which these cells make their effects	30487
@NP	different mechanisms	30487
@NP	these cells	30522
@NP	their effects	30539
@NP	most probably harnessing the whole potential of both of these cell types	30554
@NP	most	30554
@NP	the whole potential of both of these cell types	30579
@NP	the whole potential	30579
@NP	both of these cell types	30602
@NP	both	30602
@NP	these cell types	30610
@NP	the mentioned cells	30654
@NP	suitable candidates for cell therapy approaches of spinal cord injuries	30705
@NP	suitable candidates	30705
@NP	cell therapy approaches of spinal cord injuries	30729
@NP	cell therapy approaches	30729
@NP	spinal cord injuries	30756
@VP	derived mesenchymal stem cells	624
@VP	were transplanted in a rat model of sub-acute spinal cord injury	710
@VP	transplanted in a rat model of sub-acute spinal cord injury	715
@VP	were conducted	820
@VP	conducted	825
@VP	was used to produce an injury at T8 -- T9 level of spinal cord	868
@VP	used to produce an injury at T8 -- T9 level of spinal cord	872
@VP	to produce an injury at T8 -- T9 level of spinal cord	877
@VP	produce an injury at T8 -- T9 level of spinal cord	880
@VP	developing lesion cavity , 3 mm cranial and 3 mm caudal to the cavity	1018
@VP	using BBB score	1117
@VP	was done over five-week period post transplantation	1133
@VP	done over five-week period post transplantation	1137
@VP	to evaluate the reduction of cavity formation and axonal regeneration	1282
@VP	evaluate the reduction of cavity formation and axonal regeneration	1285
@VP	revealed the presence of transplanted cells in the spinal cord parenchyma	1501
@VP	was occupied with syrinx cavity in NIMSC group	1604
@VP	was significantly less than control group	1651
@VP	receiving NIMSC compared to the other two groups	1793
@VP	caused both behavioral and histological improvement that potentially makes them	1863
@VP	makes them	1932
@VP	1	2019
@VP	result in paraplegia or quadriplegia depending on the trauma site	2201
@VP	lose of sensation	2271
@VP	have difficulty in controlling urination and defecation	2313
@VP	controlling urination and defecation	2332
@VP	produced and released in the damaged area -LRB- Filbin , 2003 -RRB-	2608
@VP	takes place in the surrounding tissue site due to inflammatory factors	2707
@VP	modifies substantially the prognosis -LRB- Andrade et al. , 2008 -RRB-	2782
@VP	to reduce consequences of spinal damages -LRB- Bracken , 2001 -RRB-	2940
@VP	reduce consequences of spinal damages -LRB- Bracken , 2001 -RRB-	2943
@VP	is an issue that has raised much hope in regeneration of CNS and PNS	3011
@VP	has raised much hope in regeneration of CNS and PNS	3028
@VP	raised much hope in regeneration of CNS and PNS	3032
@VP	have been used to regenerate CNS	3109
@VP	been used to regenerate CNS	3114
@VP	used to regenerate CNS	3119
@VP	to regenerate CNS	3124
@VP	regenerate CNS	3127
@VP	have used to regenerate CNS with different levels of success	3549
@VP	used to regenerate CNS with different levels of success	3554
@VP	to regenerate CNS with different levels of success	3559
@VP	regenerate CNS with different levels of success	3562
@VP	to develop into different cell types -LRB- Caplan , 2007 -RRB-	3823
@VP	develop into different cell types -LRB- Caplan , 2007 -RRB-	3826
@VP	induced MSC into the sub-acute model of SCI	4104
@VP	compared to undifferentiated MSC -LRB- Pedram et al. , 2009 -RRB-	4195
@VP	are able to stimulate tissue sparing and neuroprotection	4700
@VP	to stimulate tissue sparing and neuroprotection	4709
@VP	stimulate tissue sparing and neuroprotection	4712
@VP	enhance outgrowth of both intact and lesioned axons	4758
@VP	aiming at improving the regeneration of neural tissue in the damaged area	5021
@VP	improving the regeneration of neural tissue in the damaged area	5031
@VP	2	5097
@VP	Highly purified cultures of OEC	5168
@VP	described by Ramon-Cueto et al. -LRB- 1998 -RRB-	5304
@VP	modified by Pearse et al. -LRB- 2007 -RRB-	5353
@VP	was removed with so much care to minimize the inclusion of any bulb nerve fiber	5404
@VP	removed with so much care to minimize the inclusion of any bulb nerve fiber	5408
@VP	to minimize the inclusion of any bulb nerve fiber	5434
@VP	minimize the inclusion of any bulb nerve fiber	5437
@VP	described	5787
@VP	were grown to confluence and grown to passage 3	5826
@VP	grown to confluence and grown to passage 3	5831
@VP	grown to confluence	5831
@VP	grown to passage 3	5855
@VP	was evaluated using p75 antibody -LRB- Rabbit polyclonal , Abcam , USA -RRB-	5899
@VP	evaluated using p75 antibody -LRB- Rabbit polyclonal , Abcam , USA -RRB-	5903
@VP	using p75 antibody -LRB- Rabbit polyclonal , Abcam , USA -RRB-	5913
@VP	To visualize and locate the OECs after transplantation	5965
@VP	visualize and locate the OECs after transplantation	5968
@VP	is a thymidine analog and marker of newly synthesized DNA	6169
@VP	synthesized	6211
@VP	was removed via extensive washing before transplantation	6228
@VP	removed via extensive washing before transplantation	6232
@VP	washing before transplantation	6254
@VP	described previously	6428
@VP	were extracted bilaterally	6554
@VP	extracted bilaterally	6559
@VP	were removed	6602
@VP	removed	6607
@VP	was inserted into the proximal end of the bone	6635
@VP	inserted into the proximal end of the bone	6639
@VP	was flushed into sterile cryovials and stored on ice	6693
@VP	flushed into sterile cryovials and stored on ice	6697
@VP	flushed into sterile cryovials	6697
@VP	stored on ice	6732
@VP	was cultured in T25 flasks	6780
@VP	cultured in T25 flasks	6784
@VP	then cultured in DMEM/F12 containing 10 % FBS and 1 % penicillin/streptomycin	6823
@VP	containing 10 % FBS and 1 % penicillin/streptomycin	6849
@VP	adhered cells were trypsinized and resuspended in the fresh medium in new flasks	6922
@VP	were trypsinized and resuspended in the fresh medium in new flasks	6936
@VP	trypsinized and resuspended in the fresh medium in new flasks	6941
@VP	were grown to confluence and used at passage 3	7010
@VP	grown to confluence and used at passage 3	7015
@VP	grown to confluence	7015
@VP	used at passage 3	7039
@VP	using fluorescein	7145
@VP	to differentiate into adipocytes and osteoblasts , as previously described	7492
@VP	differentiate into adipocytes and osteoblasts , as previously described	7495
@VP	described	7556
@VP	was employed to identify adipocytes and osteoblasts , respectively	7628
@VP	employed to identify adipocytes and osteoblasts , respectively	7632
@VP	to identify adipocytes and osteoblasts , respectively	7641
@VP	identify adipocytes and osteoblasts , respectively	7644
@VP	carrying the green fluorescent protein -LRB- GFP -RRB- gene	7720
@VP	described previously	7804
@VP	defined as day 1 , 2 mL of virus solution and 2 mL of complete medium	7889
@VP	forming unit -LRB- PFU -RRB-	7976
@VP	were added to about 106 cells	7996
@VP	added to about 106 cells	8001
@VP	to about 106 cells	8007
@VP	about 106 cells	8010
@VP	was replaced by complete fresh medium	8074
@VP	replaced by complete fresh medium	8078
@VP	followed by 0.05 % trypsin/0 .03 % EDTA for 5 min	8204
@VP	was used to ensure that cells were positively labeled before transplantation	8275
@VP	used to ensure that cells were positively labeled before transplantation	8279
@VP	to ensure that cells were positively labeled before transplantation	8284
@VP	ensure that cells were positively labeled before transplantation	8287
@VP	were positively labeled before transplantation	8305
@VP	labeled before transplantation	8321
@VP	described previously in details -LRB- Deng et al. , 2001 -RRB-	8445
@VP	were changed every 2 -- 3 days	8680
@VP	changed every 2 -- 3 days	8685
@VP	were ready for engraftment	8742
@VP	To do so	8892
@VP	do so	8895
@VP	using mouse monoclonal anti-beta-tubulin III -LRB- 1:50 , Abcam , USA -RRB-	9040
@VP	associated protein 2 -LRB- MAP2 , 1:50 , Abcam , USA -RRB-	9134
@VP	using Fogarty catheter as detailed previously -LRB- Vanicky ' et al. , 2001	9373
@VP	detailed previously -LRB- Vanicky ' et al. , 2001	9399
@VP	was done at T10 vertebral level in anesthetized rats using dental drill	9464
@VP	done at T10 vertebral level in anesthetized rats using dental drill	9468
@VP	using dental drill	9517
@VP	was filled with saline and connected to an air	9567
@VP	filled with saline and connected to an air	9571
@VP	filled with saline	9571
@VP	connected to an air	9594
@VP	held in a precise sampling device	9644
@VP	was inserted into the epidural space	9692
@VP	inserted into the epidural space	9696
@VP	advanced cranially for 1 cm	9733
@VP	rested at T8 -- T9 level of the spinal cord	9796
@VP	rapidly inflated with a defined volume of saline -LRB- 15 µl -RRB- for 5 min	9859
@VP	was deflated and removed	9948
@VP	deflated and removed	9952
@VP	were closed in layers	9996
@VP	closed in layers	10001
@VP	were kept alone in large cages	10039
@VP	kept alone in large cages	10044
@VP	was performed at least twice daily until reflex bladder was established	10097
@VP	performed at least twice daily until reflex bladder was established	10101
@VP	was established	10153
@VP	established	10157
@VP	was carried out for one week	10230
@VP	carried out for one week	10234
@VP	followed the guidelines of the Iran Animal Care Committee	10276
@VP	were approved by the faculty of veterinary medicine animal care committee	10338
@VP	approved by the faculty of veterinary medicine animal care committee	10343
@VP	were harvested from culture via trypsinization	10502
@VP	harvested from culture via trypsinization	10507
@VP	were centrifuged , resuspended in fresh DMEM/F12 and counted	10561
@VP	centrifuged , resuspended in fresh DMEM/F12 and counted	10566
@VP	centrifuged	10566
@VP	resuspended in fresh DMEM/F12	10579
@VP	counted	10613
@VP	were kept on ice prior to surgery	10652
@VP	kept on ice prior to surgery	10657
@VP	were anesthetized	10716
@VP	was made in the vertebral arches of T8 and/or T9 using a micromotor	10751
@VP	made in the vertebral arches of T8 and/or T9 using a micromotor	10755
@VP	using a micromotor	10800
@VP	connected to a microinjector	10856
@VP	was 2 µl/min	11108
@VP	was kept in place for an additional 1 min to minimize leakage upon withdrawal	11143
@VP	kept in place for an additional 1 min to minimize leakage upon withdrawal	11147
@VP	to minimize leakage upon withdrawal	11185
@VP	minimize leakage upon withdrawal	11188
@VP	were randomly divided into 3 groups	11227
@VP	divided into 3 groups	11241
@VP	serving as control	11440
@VP	was injected as above -LRB- n = 7 -RRB-	11490
@VP	injected as above -LRB- n = 7 -RRB-	11494
@VP	were closed in layers	11546
@VP	closed in layers	11551
@VP	replating another aliquot in tissue culture flask	11665
@VP	growing them for several days	11719
@VP	recorded by digital video camera at each time point	12112
@VP	analyzed by two blind researchers	12168
@VP	using SPSS version 13 -LRB- SPSS Inc. , Chicago , IL , USA -RRB-	12371
@VP	were deeply anesthetized -LRB- 70 mg/kg ketamine , 10 mg/kg xylazine -RRB-	12524
@VP	was removed and postfixed overnight in 4 % PFA at 4 ◦ C.	12679
@VP	removed and postfixed overnight in 4 % PFA at 4 ◦ C.	12683
@VP	To carry out immunohistological analysis	12734
@VP	carry out immunohistological analysis	12737
@VP	was embedded in paraffin	12792
@VP	embedded in paraffin	12796
@VP	sectioned longitudinally at 10 and 20 µm thicknesses , by a microtome	12821
@VP	using anti BrdU HRP conjugated antibody -LRB- 1/2000 , AbD Serotec , USA -RRB-	13084
@VP	conjugated antibody -LRB- 1/2000 , AbD Serotec , USA -RRB-	13104
@VP	adding diaminobenzidine -LRB- DAB -RRB- -LRB- Sigma , USA -RRB-	13203
@VP	performed according to that previously described -LRB- Parr et al. , 2008 -RRB-	13285
@VP	previously described	13313
@VP	were processed for H&E staining	13405
@VP	processed for H&E staining	13410
@VP	was traced using Image J software	13477
@VP	traced using Image J software	13481
@VP	using Image J software	13488
@VP	was counted as part of the lesion	13552
@VP	counted as part of the lesion	13556
@VP	covering a total of 1 cm of spinal cord	13705
@VP	were calculated	13819
@VP	calculated	13824
@VP	examined after adding matched HRPconjugated secondary antibody and DAB	14112
@VP	adding matched HRPconjugated secondary antibody and DAB	14127
@VP	matched HRPconjugated secondary antibody and DAB	14134
@VP	using Image J software	14296
@VP	3	14505
@VP	to verify culture purity	14861
@VP	verify culture purity	14864
@VP	represent 100 µm	14898
@VP	labeled undifferentiated MSC and immunostaining of NIMSC	14951
@VP	labeled cells -LRB- B -RRB-	15062
@VP	revealed a transduction rate of 95 % -LRB- C -RRB-	15094
@VP	represent 100 µm	15228
@VP	Captured images from videos	15255
@VP	studied groups	15399
@VP	assessed by BBB scoring system	15516
@VP	scoring system	15532
@VP	was significantly higher than OEC and control group -LRB- * P < 0.05 -RRB-	15570
@VP	are expressed as the means ± SD	15729
@VP	expressed as the means ± SD	15733
@VP	± SD	15756
@VP	based on the dead animals during the course of study	15795
@VP	labeled transplanted cells in the injured tissue	15875
@VP	using HRP	16085
@VP	conjugated antibody	16095
@VP	represent 100 µm	16127
@VP	was significantly less than the control group -LRB- * P < 0.05 -RRB-	16347
@VP	was not statistically significant -LRB- P > 0.05 -RRB- -LRB- B -RRB-	16478
@VP	are expressed as the means ± SD	16533
@VP	expressed as the means ± SD	16537
@VP	± SD	16560
@VP	represent 100 µm	16577
@VP	studied groups -LRB- control , OEC and NIMSC -RRB- -LRB- A -RRB-	16662
@VP	treated group	16908
@VP	are expressed as the means ± S.D.	16993
@VP	expressed as the means ± S.D.	16997
@VP	± S.D.	17020
@VP	represent 100 µm	17038
@VP	isolated from bone marrow	17134
@VP	were detected using flowcytometry analysis	17160
@VP	detected using flowcytometry analysis	17165
@VP	using flowcytometry analysis	17174
@VP	were negative for CD31 , CD44 , CD45 -LRB- Fig. 1A -RRB-	17308
@VP	stained with Oil Red O and Alizarin Red	17408
@VP	To verify the purification of the enriched population	17631
@VP	verify the purification of the enriched population	17634
@VP	were stained with anti-P75 antibody	17692
@VP	stained with anti-P75 antibody	17697
@VP	were positive for this marker -LRB- Fig. 1E -- G -RRB-	17784
@VP	labeling MSCs	17831
@VP	were transduced with GFP bearing lentiviral vectors	17852
@VP	transduced with GFP bearing lentiviral vectors	17857
@VP	using fluorescent microscope and DAPI nuclear staining	17950
@VP	to be positive for GFP -LRB- Fig. 2A -- C -RRB-	18040
@VP	be positive for GFP -LRB- Fig. 2A -- C -RRB-	18043
@VP	driving the MSCs toward neural lineage	18108
@VP	began to change within a day	18164
@VP	to change within a day	18170
@VP	change within a day	18173
@VP	developed characteristic round cell bodies with several branching extensions	18204
@VP	was bipolar or multipolar in shape	18323
@VP	appeared to make contact with neighboring cells	18362
@VP	to make contact with neighboring cells	18371
@VP	make contact with neighboring cells	18374
@VP	differentiated cells	18601
@VP	using BBB scale , in which the maximum hindlimb motor function score was 21	18912
@VP	was 21	18980
@VP	had a score of 21 before making the injury	18997
@VP	making the injury	19022
@VP	were reduced to 0 -- 1 soon after the compression	19055
@VP	reduced to 0 -- 1 soon after the compression	19060
@VP	subjected to contusion and then injected with NIMSCs	19201
@VP	subjected to contusion	19201
@VP	then injected with NIMSCs	19228
@VP	was 8.625 ± 1.03 in the OEC treated group and 7.375 ± 0.916 in the control ones	19366
@VP	treated group and 7.375 ± 0.916 in the control ones	19394
@VP	supported plantar steps with forelimb and hindlimb coordination	19535
@VP	were sweeping with no weigh support	19637
@VP	weigh	19659
@VP	could move all three joint extensively	19709
@VP	move all three joint extensively	19715
@VP	unable to sweep	19763
@VP	do planter step -LRB- Fig. 3 , Supplementary videos 1 -- 6 -RRB-	19782
@VP	was significantly better than OEC and control groups -LRB- P < 0.05 -RRB-	19887
@VP	happened during the first week	20150
@VP	was the end point of the experiment -LRB- Fig. 4 -RRB-	20304
@VP	died from the control group in each week	20521
@VP	follow up in the NIMSC treated group no rat	20591
@VP	treated group no rat	20614
@VP	treated group	20651
@VP	died at the first week -LRB- Fig. 5 -RRB-	20678
@VP	speaking , at the end of the study rats receiving cell treatment	20738
@VP	receiving cell treatment	20777
@VP	not shown	20865
@VP	Finding transplanted cells in tissue Five weeks after transplantation	20882
@VP	stained cells using HRP conjugated secondary antibody against GFP and BrdU	21033
@VP	using HRP conjugated secondary antibody against GFP and BrdU	21047
@VP	conjugated secondary antibody against GFP and BrdU	21057
@VP	was calculated after H&E staining -LRB- Fig. 7A -RRB-	21255
@VP	calculated after H&E staining -LRB- Fig. 7A -RRB-	21259
@VP	showed a slight decrease compared to OEC group but this difference	21493
@VP	was not statistically significant -LRB- P > 0.05 -RRB- -LRB- Fig. 7B -RRB-	21560
@VP	to evaluate axonal density -LRB- Fig. 8A -RRB-	21692
@VP	evaluate axonal density -LRB- Fig. 8A -RRB-	21695
@VP	treated	21838
@VP	treated group	21933
@VP	4	22019
@VP	showing great promises for the translation of MSC research into the clinics	22212
@VP	showed better outcomes in using NIMSC than OECs	22301
@VP	using NIMSC than OECs	22327
@VP	highlighted the enormous capacity of NIMSC to survive in the injured tissue	22608
@VP	to survive in the injured tissue	22651
@VP	survive in the injured tissue	22654
@VP	reducing the cavitation	22709
@VP	facilitating axonal growth	22734
@VP	were not achieved to the same extent by OEC	22826
@VP	achieved to the same extent by OEC	22835
@VP	have been used to bring about spinal damage in animal models	22887
@VP	been used to bring about spinal damage in animal models	22892
@VP	used to bring about spinal damage in animal models	22897
@VP	to bring about spinal damage in animal models	22902
@VP	bring about spinal damage in animal models	22905
@VP	have used the pressure method using Fogarty catheter	22967
@VP	used the pressure method using Fogarty catheter	22972
@VP	using Fogarty catheter	22997
@VP	are those showing improvement over time	23084
@VP	exerting this much of pressure per weight of rats	23174
@VP	would occur over time	23253
@VP	occur over time	23259
@VP	would rise up from 0 -- 1 to about 8.5 -LRB- Vanicky ' et al. , 2001 -RRB-	23333
@VP	rise up from 0 -- 1 to about 8.5 -LRB- Vanicky ' et al. , 2001 -RRB-	23339
@VP	is pretty close to the result mentioned in study of Vanicky et al.	23495
@VP	mentioned in study of Vanicky et al.	23525
@VP	might be due to variations between animals	23579
@VP	be due to variations between animals	23585
@VP	caused at the time of medium injection	23657
@VP	associated with astroglial scarring	23847
@VP	limit the spontaneous reorganization of the neural pathways	23884
@VP	increasing host cellular or axonal survival or decreasing host glial scaring	24300
@VP	scaring	24369
@VP	may replace lost cells	24536
@VP	replace lost cells	24540
@VP	was injected into the spinal damaged tissue	24837
@VP	injected into the spinal damaged tissue	24841
@VP	would respond to environmental stimuli	24887
@VP	respond to environmental stimuli	24893
@VP	showed hair follicle stem cells transplanted into sciatic injured nerve	25279
@VP	transplanted into sciatic injured nerve	25311
@VP	enhance the rate of nerve regeneration	25420
@VP	using neural restricted progenitor cells	25724
@VP	could survive in the nerve constructs as long as eight weeks	26383
@VP	survive in the nerve constructs as long as eight weeks	26389
@VP	showed desirable electrophysiological features -LRB- Lin et al. , 2011 -RRB-	26470
@VP	based therapy	26835
@VP	is the survival of the grafted cells	26849
@VP	labeled OECs using BrdU	26908
@VP	using BrdU	26921
@VP	could detect them in the target tissue at the end of study	26936
@VP	detect them in the target tissue at the end of study	26942
@VP	labeled NIMSCs	27010
@VP	to survive within the spinal tissue of recipient rats	27101
@VP	survive within the spinal tissue of recipient rats	27104
@VP	enhance axonal growth in surviving neurons	28016
@VP	could contribute to functional recovery -LRB- Kerr et al. , 2003 -RRB-	28370
@VP	contribute to functional recovery -LRB- Kerr et al. , 2003 -RRB-	28376
@VP	can survive after transplantation	28730
@VP	survive after transplantation	28734
@VP	caused significant improvement in the BBB score compared to control group	28797
@VP	compared to control group	28845
@VP	to control group	28854
@VP	control group	28857
@VP	was significantly greater than control group	28911
@VP	is not useful for spinal repair in animal model -LRB- Takami et al. , 2002 -RRB-	29326
@VP	could be attributed to many factors including variations in culture protocols	29551
@VP	be attributed to many factors including variations in culture protocols	29557
@VP	attributed to many factors including variations in culture protocols	29560
@VP	isolated OECs	29666
@VP	support regrowth of rubrospinal , raphaespinal and CGRP positive fibers	29819
@VP	being expanded and subcultured for 25 days in vitro	30021
@VP	expanded and subcultured for 25 days in vitro	30027
@VP	being transplanted into the animals	30081
@VP	transplanted into the animals	30087
@VP	Using such short term in vitro	30118
@VP	can justify the desired result in our study	30158
@VP	justify the desired result in our study	30162
@VP	tested in this work , on each own	30398
@VP	make their effects	30534
@VP	probably harnessing the whole potential of both of these cell types	30559
